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1. INTRODUCTION 
Arterial hypertension is a leading cause of death globally, which affects 
approximately 1 billion people worldwide (World Health Organization 2009). 
The value of elevated blood pressure (BP) as a predictor of future cardi-
ovascular disease (CVD) is firmly established (Kannel 1996). However, only a 
small fraction of hypertensive patients have elevated BP levels alone, with the 
great majority presenting additional risk factors, leading to the development of 
subclinical target organ damage and increased total cardiovascular risk (Mancia 
et al. 2007). Furthermore, cardiovascular risk cannot be fully explained by tra-
ditional risk factors (Cohn et al. 2004). 
The vascular tree is lined with the endothelium. Endothelial cells produce 
several vasoactive substances, including nitric oxide (NO), which is the main 
vasodilating and a principal antiatherogenic biomolecule in the human arteries 
(Davignon and Ganz 2004). It has been shown that NO-mediated endothelium-
dependent vasodilation (EDV), a hallmark of endothelial function, is decreased 
in hypertension (Panza et al. 1990). Endothelial dysfunction is considered as an 
early process in arterial stiffening and atherosclerotic lesion formation 
(Wilkinson et al. 2002b; Halcox et al. 2009). There is evidence that early inter-
vention in hypertensive patients is prognostically important (Julius et al. 2004). 
Consequently, several biochemical and functional markers of endothelial 
dysfunction have been acknowledged in order to more precisely and timely 
stratify cardiovascular risk in these patients (Mancia et al. 2007). Other 
independent predictors of cardiovascular risk, oxidative stress (OxS) (Heitzer et 
al. 2001) and inflammation (Ridker et al. 2002), are increased in hypertension 
(Russo et al. 1998; Kampus et al. 2006). Moreover, reversing non-physiological 
levels of OxS and inflammation reduces endothelial dysfunction (Taddei et al. 
1998; Mäki-Petäjä et al. 2007) and the progression of atherosclerosis (Nissen et 
al. 2005; Ono et al. 2008). Thus, the maintenance of both OxS and 
inflammation may have an additional merit in antihypertensive therapy.  
Large comparative studies and meta-analyses have shown that brachial BP 
reduction per se reduces cardiovascular risk (Staessen et al. 2001; ALLHAT 
Officers and Coordinators 2002; Turnbull et al. 2003). The European Society of 
Hypertension (ESH) and the European Society of Cardiology (ESC) recom-
mend lowering of BP below 140/90 mmHg in essential hypertension (Mancia et 
al. 2007). Although a large range of antihypertensive drugs are available, less 
than 30% of the treated hypertensive patients are at or below target BP levels 
(Primatesta et al. 2001; Grassi et al. 2011). A significant number of these 
patients remain above target level despite adequate compliance with therapy. 
Current hypertension guidelines emphasise the need for treatment indi-
vidualisation based on the level of BP, presence of cardiovascular risk factors, 
subclinical target organ damage, or concomitant conditions (Mancia et al. 
2009). Essential hypertension is characterised by an altered haemodynamic 
profile of the patients (Franklin et al. 1997). There is evidence that the assess-
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ment of the haemodynamic profile of hypertensive subjects could predict the 
reduction of BP with antihypertensive therapy (Smith et al. 2006; Protogerou 
et al. 2009a). Hence, haemodynamic profiling could lead to improved and more 
rapid BP control, and a reduction in the number of antihypertensive drugs 
required in an individual patient.  
Traditionally, BP is measured from the brachial artery. However, BP in the 
brachial (peripheral) artery and in the aorta (central artery) differ significantly 
due to arterial stiffness and pulse wave reflection phenomena. There is an 
increasing amount of evidence that central BP is more relevant than brachial BP 
for the development of subclinical target organ damage (Agabiti-Rosei et al. 
2007a; Wang et al. 2009). Furthermore, antihypertensive drugs exert differential 
effects on brachial and central BP. Nitrates, calcium channel blockers (CCBs), 
angiotensin converting enzyme inhibitors (ACEIs), and angiotensin II receptor 
blockers (ARBs) have been shown to effectively reduce both brachial and cen-
tral BP (Protogerou et al. 2009b). Data about beta-blockers (BBs) are contro-
versial. The most extensively studied conventional BB, atenolol, has been 
shown to effectively reduce brachial BP, but to have minimal or no effect on 
central BP (Williams et al. 2006; Mackenzie et al. 2009). This detrimental 
effect of atenolol is considered as an explanation for its inferiority to other anti-
hypertensive drugs in reducing cardiovascular events in patients with uncompli-
cated hypertension (Wilkinson et al. 2006). However, BBs are pharmaco-
logically heterogeneous (Panjrath and Messerli 2006) and newer BBs (e.g. 
nebivolol) may have a greater effect on central BP (Dhakam et al. 2008; 
Mahmud and Feely 2008). There are no data about the effect of metoprolol 
succinate, the most widely used conventional BB in Northern and Eastern 
Europe, on central BP. 
The main purpose of the present thesis was to assess the biochemical, func-
tional, and structural parameters and properties of the vasculature in hyper-
tension, as well as to investigate the effect of antihypertensive therapy on these 
parameters. 
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2. REVIEW OF THE LITERATURE 
2.1. Arterial hypertension 
Arterial hypertension is an important public health challenge because of its high 
prevalence and association with CVD (Kearney et al. 2005). The perception of 
elevated BP as a risk factor for CVD is based on the results from the Framing-
ham Heart Study launched in 1948 (Kannel et al. 1961). To date, elevated BP 
has been identified as a major risk factor for coronary artery disease, heart 
failure, stroke, peripheral artery disease, and renal failure (Mancia et al. 2007). 
Historically, diastolic rather than systolic BP was emphasised as a predictor of 
cardiovascular events (MacMahon et al. 1990). Diastolic BP was regarded as 
the resistance that the heart had to overcome, while systolic BP was taken as a 
measure of cardiac strength (Vlachopoulos and O’Rourke 2000). However, the 
accumulating amount of data confirmed that both systolic and diastolic BP have 
continuous independent relationship with cardiovascular morbidity and mor-
tality (Kannel et al. 1971; Kannel et al. 1981; Lewington et al. 2002). Arterial 
hypertension is widely defined as persistent brachial systolic and/or diastolic BP 
>140/90 mmHg. Current ESH/ESC guidelines state that the classification of 
hypertension and its risk assessment should be based on systolic and diastolic 
BP, risk factors, subclinical target organ damage, and concomitant diseases 
(Mancia et al. 2007). Estimation of total cardiovascular risk is important for the 
choice of primary and secondary cardiovascular prevention in hypertensive 
patients. 
Treating systolic and diastolic BP until they are less than 140/90 mmHg is 
associated with an improvement in cardiovascular outcome (Mancia et al. 
2009). While lifestyle changes (e.g. smoking cessation, sodium restriction, 
weight reduction) may be appropriate, these kinds of interventions should not 
unnecessarily delay the initiation of pharmacological treatment for hyper-
tension, especially in patients at high level of risk (Mancia et al. 2007). Cur-
rently, five major classes of antihypertensive drugs – thiazide diuretics, CCBs, 
ACEIs, ARBs, and BBs – in monotherapy or combined, are suitable for the 
treatment of hypertension (Mancia et al. 2007). Despite the fact that elevated 
BP has been known to be an important risk factor for CVD for half a century 
and a variety of antihypertensive drugs are available, the target of 140/90 
mmHg has remained to be poorly achieved (Pereira et al. 2009). Furthermore, 
several large-scale comparative studies have shown that, despite similar brachial 
BP reduction, ‘older’ antihypertensive drugs are inferior to ‘newer’ anti-
hypertensive drugs in reducing cardiovascular risk (Dahlöf et al. 2002; Dahlöf 
et al. 2005). These data have called for the development of novel methods and 
markers of cardiovascular risk assessment. Moreover, the effects of anti-
hypertensive drugs on these markers have been shown to better predict cardio-
vascular outcome than brachial BP (Williams et al. 2006). 
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2.2. Central haemodynamics 
The BP is the force that the blood exerts on the vascular wall. Arterial pressure 
can be divided into the steady [mean arterial pressure (MAP)] and the pulsatile 
[pulse pressure (PP)] components (Cheriyan et al. 2010). The MAP is deter-
mined by cardiac output (CO) and vascular resistance, whereas the PP compo-
nent is influenced by left ventricular ejection, large artery stiffness, pulse wave 
reflection, and heart rate (Franklin et al. 1997). The arterial system receives 
blood in spurts from the left ventricle of the heart. In the systole, the left ven-
tricle generates a forward moving pulse wave. The increasing impedance in 
resistance arteries (small muscular arteries and arterioles) and the branching of 
arteries cause a backward reflecting pulse wave (O’Rourke 1982). Conse-
quently, the pulse waveform at any site of the arterial tree is the sum of the for-
ward traveling wave and the backward traveling wave (Nichols and O’Rourke 
2005). In healthy large conduit arteries the reflecting wave arrives to the heart in 
the diastole, thus increasing diastolic BP and improving coronary artery per-
fusion. However, in stiff arteries pulse wave velocity (PWV) is increased, i.e. 
the incident and the reflected pulse waves are accelerated, causing the reflected 
pulse wave to merge with the incident pulse wave in the systole, augmenting 
central systolic BP and PP (Williams 2004). This in turn leads to increased left 
ventricular afterload and oxygen demand and reduced coronary perfusion, 
resulting in left ventricular hypertrophy (LVH). This pulse wave reflection can 
be quantified through the measurement of augmentation index (AIx) which can 
be measured using pulse wave analysis (PWA) (Pauca et al. 2001; Van Bortel 
et al. 2001) (Figure 1). Due to the pulse pressure amplification (PPA) phe-
nomenon, systolic BP is amplified when moving from the aorta to the 
periphery. Typically, MAP and diastolic BP fall by only 1–2 mmHg. This small 
fall in MAP causes blood to flow forwards, not backwards. Consequently, the 
pulsatile components (systolic BP and PP) of central and peripheral pressures 
may vary significantly. In general, brachial systolic BP and PP tend to overes-
timate central systolic BP and PP. In younger individuals PPA is more pro-
nounced, whereas with vascular ageing amplification is reduced (Agabiti-Rosei 
et al. 2007a).  
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Figure 1. Pulse wave analysis. AIx is the ratio of augmentation pressure (AP) to PP (in 
percentage). Modified from Serg et al. 2010. 
 
 
Central haemodynamics in arterial hypertension 
Arterial hypertension is a physiologically and haemodynamically heterogeneous 
disease. Altered haemodynamics can play a central role in the development and 
perpetuation of high BP (Franklin et al. 1997). Hypertension is often considered 
to result from an increase in peripheral vascular resistance (PVR) (Julius 1990). 
Although this is largely true in middle-aged subjects with elevation of both 
systolic and diastolic BP (i.e. mixed systolic/diastolic hypertension) (Izzo 
2005), it has recently been shown that this is not true in subjects with isolated 
systolic hypertension (Mitchell et al. 2004; Yasmin et al. 2005), which is the 
most common form of hypertension in the elderly (Franklin et al. 2001) and 
prevalent in adolescents (Sorof et al. 2002) and in young adults (Mallion et al. 
2003). In young subjects with isolated systolic hypertension, PVR is normal and 
hypertension results primarily from either an elevation in CO or increased stiff-
ness of the large arteries (McEniery et al. 2005b). The mechanisms underlying 
increased arterial stiffness in young hypertensives have remained unknown. 
Long-term follow-up studies have shown that in young hypertensives with pri-
marily increased CO, CO normalises with age and is followed by an increase in 
PVR, resulting in mixed systolic/diastolic hypertension (Lund-Johansen 1994). 
In older adults with isolated systolic hypertension the main physiological 
abnormality is the stiffening of the large arteries (Franklin et al. 1997). 
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Current ESH/ESC guidelines recommend the use of a specific antihyper-
tensive drug based on level of BP, presence of cardiovascular risk factors, sub-
clinical target organ damage, or concomitant conditions (Mancia et al. 2009). 
However, haemodynamic profiling of hypertensive subjects could predict BP 
reduction with antihypertensive therapy (Smith et al. 2006; Protogerou et al. 
2009a). Hence, haemodynamic profiling could lead to improved and more rapid 
BP control, and a reduction in the number of antihypertensive drugs required in 
an individual patient. One could predict that drugs that reduce CO (i.e. BBs) 
(Conway 1983) would be more efficacious in individuals with high CO. Simi-
larly, vasodilators (i.e. alpha-blockers) could be more effective in individuals 
with increased PVR (Lund-Johansen and Omvik 1991). There is evidence that 
ARBs have BP-independent effects on arterial stiffness, thus they could be effi-
cacious in patients with high aortic PWV (Mahmud and Feely 2002). Oral 
nitrate preparations have been shown to reduce significantly AIx, indicating that 
they may be useful in patients with increased pulse wave reflection (Stokes 
et al. 2003). 
 
 
2.2.1. Central blood pressure 
2.2.1.1. Assessment of central blood pressure 
Brief history of methods for measuring central blood pressure 
Classically, central BP has been measured invasively. The first measurement of 
BP was conducted by a Cambridge University graduate, Stephen Hales (1733), 
in a series of experiments. In his classical experiment, Hales opened an artery of 
a mare, inserted a narrow brass tube into the artery and fitted a 9-foot-long ver-
tical glass tube to the pipe. The pressure of the horse’s circulation forced the 
blood up the glass tube (Booth 1977). In the early 19th century, Richard Bright 
identified increased arterial tension from the ‘hardness’ of the arterial pulse, and 
associated LVH and vascular damage to high arterial pressure (O’Rourke and 
Gallagher 1996). The pioneering studies by Marey in Paris and Mahomed in 
London (O’Rourke 1992) followed with non-invasive graphic methods to 
record the radial pulse wave at the end of the 19th century. However, interest in 
the pulse wave methodologies lapsed with the introduction of the cuff sphyg-
momanometer by Riva-Rocci in 1896 and the improvement of the method by 
Korotkov in 1905 (Hirata et al. 2006). The introduction of high-fidelity mano-
meters by Murgo and Millar in 1972 and tonometers for invasive and non-
invasive pulse wave recording (Drzewiecki et al. 1983; Kelly et al. 1989) as 
well as the development of methods to characterise and analyse the arterial 
pulse (Nichols and O’Rourke 2005) marked the ‘renaissance’ of PWA. 
Furthermore, by that time the limitations of the cuff sphygmomanometer 
(mainly the ability to only measure the extremes of the pulse in the brachial 
artery) were better recognised (O’Rourke and Gallagher 1996). 
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Current methods for measuring central blood pressure 
Invasive techniques during open chest surgery or cardiac catheterisation remain 
to be the most accurate methods of central BP measurement (Wilkinson et al. 
2010). However, these methods are not appropriate in clinical studies and 
routine practice. Several non-invasive techniques have been developed for the 
assessment of central BP (Van Bortel et al. 2008). The most widely used 
approach is to perform radial artery tonometry and then apply a radial-to-aorta 
transfer function (Sphygmocor, Atcor Medical, Australia) to calculate the aortic 
pulse waveform from the radial waveform (Laurent et al. 2006). The radial 
artery is well supported by bony tissue, making optimal applanation easy to 
achieve. Arterial tonometry is based on the principle that when the artery is 
immobilised and the arterial wall is flattened against a pressure sensor, pressure 
within the lumen is directly transmitted to the sensor (Nichols and O’Rourke 
2005). The tonometer generates a radial artery waveform which can then be 
transformed using a mathematical radial-to-aortic transfer function to derive an 
aortic waveform. By entering the data from simultaneous, non-invasive, 
oscillometric measurement of brachial BP, the waveforms and transfer function 
have been used to derive central haemodynamic indices. It has been shown that 
applanation tonometry with transfer function is a validated, accurate, and repro-
ducible method for measuring central BP (Smulyan et al. 2003; Sharman et al. 
2006). Particularly, Pauca et al. (2001) elegantly showed that the estimated 
central PP measured with the use of the transfer function calibrated with inva-
sive radial BP differed from actual aortic PP by only 0.7 ± 4.21 mmHg. Mean-
while, the Association for the Advancement of Medical Instrumentation criteria 
accept BP measurement using oscillometric sphygmomanometers to deviate by 
5 ± 8 mmHg from the gold standard (White et al. 1993). Hence, the largest 
drawback for measuring central BP using the transfer function is considered to 
be the inaccuracy of the oscillometric sphygmomanometer (Wilkinson and 
Cockcroft 2004). 
 
2.2.1.2. Clinical implications of central blood pressure 
The value of brachial BP as a predictor of future CVD is firmly established 
(Kannel 1996). Recently, greater emphasis has been placed on brachial PP, a 
surrogate measure of large artery stiffness, especially in older individuals 
(Franklin et al. 1999; Wilkinson et al. 2004; Mancia et al. 2007). However, 
there is a gradual widening of PP from the central to the peripheral arteries due 
to the PPA phenomenon. Central (aortic, carotid) systolic BP and PP are patho-
physiologically more relevant than peripheral pressures for the pathogenesis of 
CVD (Agabiti-Rosei et al. 2007a). It is central systolic BP that the left ventricle 
encounters during the systole (afterload) and aortic diastolic BP which deter-
mines coronary perfusion. Furthermore, distending pressure (MAP) in the large 
elastic-type arteries (aorta and carotid) but not in the peripheral muscular 
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arteries (brachial, radial) is the key determinant of arterial stiffening that charac-
terises accelerated vascular ageing and hypertension (Vlachopoulos et al. 
2010a). With ageing and vascular disease the stiffness of the central arteries 
approaches that of the peripheral arteries, resulting in a relative similarity of the 
values of brachial and central PP (Kotsis et al. 2011; Wojciechowska et al. 
2012), decreasing thus PPA. Central systolic BP or PP are more closely 
correlated with measures of subclinical target organ damage, such as left ven-
tricular mass (Covic et al. 2000) and carotid intima-media thickness (IMT) 
(Boutouyrie et al. 1999; Roman et al. 2007), compared to peripheral (brachial 
and radial) systolic BP or PP. It has been shown that 70% of individuals with 
high-normal brachial BP have similar aortic pressures as those with stage 1 
hypertension (McEniery et al. 2008). Thus, assessment of central BP may 
improve the identification and management of patients with elevated 
cardiovascular risk.  
Data from the Strong Heart Study showed that wider brachial PP is asso-
ciated with higher cardiovascular mortality independently of the traditional risk 
factors, LVH, and reduced ejection fraction (Palmieri et al. 2006). Subsequent 
analysis of the same study revealed that central PP is superior over brachial PP 
for prediction of cardiovascular events (Roman et al. 2007; Roman et al. 2009). 
A community based study from China showed that central systolic BP was 
more strongly related to target organ indices, such as left ventricular mass, 
carotid IMT, estimated glomerular filtration rate (eGFR), and cardiovascular 
mortality than brachial BP (Wang et al. 2009). The predictive value of central 
BP for all-cause and cardiovascular mortality has been shown in patients with 
end-stage renal disease (Safar et al. 2002) and coronary artery disease (Chirinos 
et al. 2005). Furthermore, central systolic BP, but not brachial BP, inde-
pendently predicts cardiovascular events and cardiovascular mortality in the 
elderly (Pini et al. 2008). The Conduit Artery Function Evaluation (CAFE) 
study showed that central PP is significantly associated with a post hoc-defined 
composite outcome of cardiovascular events/procedures and development of 
renal impairment in hypertensive patients, suggesting that lowering central BP 
rather than brachial BP may be a more important goal of antihypertensive 
treatment (Williams et al. 2006).  
 
2.2.1.3. Antihypertensive therapy and central blood pressure 
The largest hypertension study to date, the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT Officers and 
Coordinators 2002), and meta-analyses (Staessen et al. 2001; Turnbull et al. 
2003) have shown that in hypertensive patients brachial BP lowering per se 
improves cardiovascular outcome. However, several large-scale hypertension 
trials have demonstrated that ‘newer’ antihypertensive drugs may reduce 
cardiovascular outcome beyond BP control. Particularly, the Losartan Inter-
vention For Endpoint reduction in hypertension (LIFE) study (Dahlöf et al. 
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2002) and the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) (Dahlöf 
et al. 2005) underlined the ‘beyond BP reduction’ paradox where an  ACEI, an 
ARB, or a CCB were superior to a conventional BB atenolol in reducing 
cardiovascular events. There is an accumulating amount of evidence that this 
‘beyond (brachial) BP reduction’ paradox can be explained by the effect of 
antihypertensive drugs on central BP. 
It has been shown that the reduction in central BP but not MAP by anti-
hypertensive treatment is involved in the reduction in a major subclinical target 
organ damage marker, carotid IMT (Boutouyrie et al. 2000). The results from 
the Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind 
(REASON) study show that the regression of left ventricular mass with long-
term antihypertensive therapy is linked to the reduction in central and not 
brachial BP (de Luca et al. 2004). 
Although nitrates are not routinely used in the management of essential 
hypertension, they were the first drug group whose effects on central BP were 
tested. In one of the first of these studies, Kelly et al. (1990) demonstrated that a 
0.3 mg sublingual dose of glyceryl trinitrate (GTN) reduced central systolic BP 
markedly more than brachial systolic BP (22.1 vs. 11.8 mmHg, respectively). 
However, to date, only acute effects of low- and high-dose nitrates on central 
BP have been studied (Stokes et al. 2003).  
‘Newer’ antihypertensive drugs, such as ACEIs (Jiang et al. 2007), ARBs 
(Dhakam et al. 2006) and CCBs (Morgan et al. 2004), are powerful vasodilators 
which effectively reduce central BP. Due to the reduction in PVR, they have 
been shown to shift the effective reflection distance more distally, thus delaying 
the arrival of the reflected wave at the central artery (Morgan et al. 2004; 
Dhakam et al. 2006). The long-term (one-year) REASON study highlighted the 
superiority of an ACEI/diuretic (perindopril/indapamide) combination over 
atenolol in reducing central BP (Asmar et al. 2001). The results from the 
REASON study were taken further in a study by Jiang et al. (2007), which 
allowed to show that while an ACEI enalapril effectively reduced central BP, 
indapamide had no effect on central BP ‘beyond’ brachial BP. Hence, the 
results of the REASON study could be attributed to angiotensin converting 
enzyme inhibition alone. The LIFE study demonstrated the superiority of an 
ARB losartan over atenolol in reducing cardiovascular events and LVH (Dahlöf 
et al. 2002). Whether these effects of an ARB could be attributed to its effects 
on central BP were tested by Dhakam et al. (2006). In this study an ARB 
eprosartan and atenolol reduced brachial BP to a similar degree while 
eprosartan reduced central BP and plasma brain natriuretic peptide (marker of 
heart afterload) significantly more than atenolol. The CCBs have been shown to 
effectively reduce central BP in short- (Morgan et al. 2004) and long-term 
(London et al. 1994) studies. Comparisons between combination therapies have 
also been conducted regarding their effects on central BP. The ASCOT 
demonstrated superiority in cardiovascular outcomes from primary treatment of 
hypertension with a CCB/ACEI (amlodipine/perindopril) combination 
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compared to a BB/thiazide diuretic (atenolol/bendroflumethiazide) combination 
(Dahlöf et al. 2005). The CAFE study, a substudy of ASCOT, including 2199 
patients with hypertension, demonstrated that despite similar brachial BP 
reduction, the CCB treatment arm was substantially superior to the BB 
treatment arm in lowering central BP, which may explain the outcome data 
(Williams et al. 2006). The superiority of a CCB/ARB combination over a 
combination including a CCB and a BB or a diuretic have been demonstrated in 
the EXPLOR study (Boutouyrie et al. 2010) and in a study by Matsui et al. 
(2009). Several studies have shown that diuretics have a neutral or negative 
effect on central BP, i.e. without a favourable effect beyond brachial BP 
reduction (Protogerou et al. 2009b). 
The BBs are beta-adrenoceptor antagonists. However, the mechanisms 
leading to BP reduction with these agents have remained unclear (Cheriyan et 
al. 2010). It has been suggested that the BBs have antihypertensive effects 
owing to a decrease in CO, inhibition of renin secretion, central sympathetic 
outflow, and the release of noradrenaline from postganglionic adrenergic nerve 
endings; and resetting of baroreceptor levels (Panjrath and Messerli 2006). The 
BBs significantly reduce heart rate and consequently increase the duration of 
the systole. This causes the reflecting pulse wave to arrive in the heart during 
the systole, concomitantly increasing the afterload and central systolic BP. 
Indeed, the most extensively studied conventional BB, atenolol, has been shown 
to effectively reduce brachial BP but to have a minimal or no effect on central 
BP (Williams et al. 2006; Mackenzie et al. 2009). However, the BBs vary con-
siderably in their chemical and pharmacodynamic properties (Panjrath and 
Messerli 2006). The hypothesis that the inferiority of atenolol in reducing 
central BP is a class effect of BBs has recently been questioned (Wilkinson et 
al. 2006). Dhakam et al. (2008) showed that nebivolol, a novel vasodilating BB, 
decreases central systolic BP more than atenolol despite their similar reduction 
in brachial BP. Atenolol is a relatively selective beta-1 adrenoceptor antagonist 
and has a weak effect on peripheral vascular tone (Burns et al. 2004). Newer 
BBs, e.g. nebivolol, are more beta-1 adrenoceptor selective but have substantial 
vasodilating properties due to several mechanisms. Firstly, they induce endo-
thelial NO production in the endothelium (Cockcroft et al. 1995; McEniery et 
al. 2004), secondly, they stimulate beta-3 adrenoceptors which mediate NO 
release (Ladage et al. 2006), and thirdly, they reduce OxS (Troost et al. 2000). 
Vasodilating BBs have additional beneficial haemodynamic effects: they reduce 
heart rate to a lesser degree compared to atenolol and have a neutral effect on 
CO (Kamp et al. 2003). However, there are no data about the effect of 
metoprolol succinate, the most widely used BB in Northern and Eastern Euro-
pean countries, on central BP. 
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2.2.2. Arterial stiffness 
The arterial wall is divided into three concentric layers: the intima, the media, 
and the adventitia. Functionally, there are two types of arteries. Firstly, there are 
large elastic arteries (i.e. aorta, common carotid artery), which can distend and 
accommodate large volumes of blood during the systole because the media is 
composed of concentric layers of elastic fibres. Secondly, there are intermediate 
size muscular arteries (i.e. femoral and brachial arteries), with a relatively thick 
media, composed mainly of smooth muscle fibres that allow them to regulate 
blood flow by constriction and dilation (Nichols and O’Rourke 2005). 
With ageing and CVD, the cushion and conduit functions of the large 
arteries are impaired (Benetos et al. 1993; O’Rourke 1995). In this regard two 
distinct terms, atherosclerosis and arteriosclerosis, often used interchangeably, 
can be distinguished. Atherosclerosis (e.g. due to hypercholesterolaemia and 
smoking) is primarily an intima disease, and is almost exclusively associated 
with the disturbance of conduit function, resulting in narrowing of arteries. 
Arteriosclerosis, which is characteristic of hypertension and ageing, results from 
the degeneration of the arterial media with fractures and fragmentation of elastic 
lamellae, increased collagen and calcium content, and dilation and hypertrophy 
of the large arteries and the aorta, hence causing increased arterial stiffness 
(Avolio et al. 1998). Arterial stiffness can be defined as a loss of compliance 
function of the large arteries (Laurent et al. 2006). In addition to structural 
determinants, arterial stiffness is strongly affected by endothelial cell signalling 
(Wilkinson et al. 2002b) and vascular smooth muscle cell tone (Zieman et al. 
2005).  
 
2.2.2.1. Clinical implications of arterial stiffness 
Measurement of PWV is regarded as the most simple, non-invasive, robust, 
reproducible, and direct method to determine arterial stiffness (Laurent et al. 
2006). Aortic PWV or carotid PWV is used for stiffness measurement in the 
elastic arteries, whereas muscular artery stiffness can be measured using 
femoro-tibial or brachial PWV. In contrast to the large arteries, the stiffness of 
the muscular arteries does not markedly change with ageing (Benetos et al. 
1993; Vermeersch et al. 2008; Ruitenbeek et al. 2008). Indeed, there is a body 
of evidence that aortic stiffness but not muscular artery stiffness predicts 
cardiovascular events (Mitchell et al. 2010). Furthermore, aortic stiffness has 
been shown to have a better predictive value than carotid stiffness in hyper-
tensive patients (Paini et al. 2006). Aortic PWV is considered as the “gold stan-
dard” measurement of regional arterial stiffness (Laurent et al. 2006). Aortic 
PWV is usually measured using the foot-to-foot velocity method from the 
common carotid artery and the femoral artery, and the time delay (in seconds) 
between the feet of the two waveforms. The distance covered by the waves is 
usually measured using a surface distance between the two recording sites 
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(metres). The PWV is calculated as the distance travelled by the pulse wave 
divided by the time taken to travel the distance (Laurent et al. 2006). Arterial 
stiffness is considered a marker of subclinical target organ damage in the latest 
ESH/ESC hypertension guidelines (Mancia et al. 2007). According to these 
guidelines, the cut-off value of increased aortic PWV, using the direct distance 
between the carotid and femoral sites, is >12 m/s. Furthermore, reference values 
of aortic PWV have been developed (Boutouyrie and Vermeersch 2010) for 
different age groups as arterial stiffness is a cumulative measure of previous 
cardiovascular risk factors. 
Arterial stiffness is considered the main determinant of PP increase in 
hypertension, thus causing isolated systolic hypertension, especially in the 
elderly (Franklin et al. 1997). Arterial stiffness is associated with a number of 
cardiovascular risk factors, e.g. ageing, smoking, impaired glucose tolerance, 
diabetes, hypercholesterolaemia, and obesity (Wilkinson et al. 2004; Laurent 
et al. 2006). There is a large amount of evidence that aortic PWV is an inde-
pendent predictor of coronary and cardiovascular events (Boutouyrie et al. 
2002; Terai et al. 2008), fatal strokes (Laurent et al. 2003), and cardiovascular 
and all-cause mortality (Laurent et al. 2001) in the general population and in a 
range of clinical conditions (Laurent et al. 2006). Currently as many as 19 
studies, the majority of them included in a recent meta-analysis (Vlachopoulos 
et al. 2010b), have consistently shown the independent predictive value of 
aortic PWV for fatal and non-fatal cardiovascular events in various populations. 
Arterial stiffness can thus be considered an intermediate end-point of cardio-
vascular events. The aforementioned meta-analysis showed that with a 1 m/s 
increase of aortic PWV the risk of cardiovascular events increases by 14% and 
cardiovascular and all-cause mortality increases by 15% (Vlachopoulos et al. 
2010b).  
Increased arterial stiffness increases the velocity of the incident and reflected 
pulse waves, which in turn shifts pulse wave reflections from the diastole to the 
systole. This phenomenon can be described with AIx, which is defined as the 
difference between the second and first systolic peaks expressed as a percentage 
of central PP. The AIx is positively correlated with age and inversely with heart 
rate and height (Kampus et al. 2006). The AIx is an indirect surrogate marker of 
aortic stiffness (Laurent et al. 2006). A recent meta-analysis showed that AIx is 
an independent predictor of cardiovascular events and all-cause mortality 
(Vlachopoulos et al. 2010a). There is evidence that age-related changes in AIx 
and aortic PWV are nonlinear, with AIx increasing more in younger individuals, 
whereas changes in aortic PWV are more prominent in older individuals 
(McEniery et al. 2005a; Kampus et al. 2007). These data suggest that AIx might 
be a more sensitive measure of arterial stiffening in younger individuals while 
aortic PWV is probably a better marker in older individuals. 
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2.2.2.2. Antihypertensive therapy and arterial stiffness 
Firstly, antihypertensive drugs may have direct, BP-independent effects on 
arterial stiffness, occurring via a modification of the elastic components of the 
arterial wall, i.e. vascular smooth muscle cells, elastin, and collagen. Secondly, 
the effects can be indirect, BP-dependent; in elastic tubes stiffness is reduced 
with lower distending pressure (Vlachopoulos and Stefanadis 2008). The 
structural degeneration that underlies arterial stiffness is largely irreversible, 
which emphasises the importance of early prevention of arterial stiffening with 
non-pharmacological interventions (Sakuragi et al. 2010). This is confirmed by 
recent data showing that increased arterial stiffness (measured using PP or 
aortic PWV) predicts the inferior BP lowering effects of antihypertensive drugs 
(Mackenzie et al. 2009; Protogerou et al. 2009a). Furthermore, the de-stiffening 
effect of antihypertensive drugs is time-dependent, emphasising the importance 
of long-term trials (Mahmud and Feely 2003).  
Reduction in arterial stiffness with antihypertensive drugs is generally 
explained by the reduction in MAP (Payne et al. 2010). However, in clinical 
trials differences in arterial stiffness change with different antihypertensive 
drugs have emerged despite similar BP reduction. The ACEIs (Tropeano et al. 
2006; Mahmud and Feely 2008) and ARBs (Mahmud and Feely 2002) seem to 
have a superior effect on arterial stiffness regardless of BP reduction (Vlacho-
poulos and Stefanadis 2008). It has been suggested that ACEIs and ARBs may 
have additional de-stiffening effects due to their anti-inflammatory and anti-
fibrotic characteristics and improvement in endothelial function (Safar 2010). 
The BP-independent effect of another group of vasodilators, the CCBs, on arte-
rial stiffness was first shown by Asmar et al. (1993). In that study the CCB 
felodipine and hydrochlorothiazide reduced similarly brachial BP but only 
felodipine reduced PWV. More recently, Matsui et al. (2009) demonstrated that 
after 24 weeks of treatment ARB/CCB and ARB/diuretic combinations reduced 
brachial BP to the same extent. However, the ARB/CCB combination showed a 
significantly greater reduction in aortic PWV (Matsui et al. 2009). Nitrates 
(Laurent et al. 1992), alpha-blockers (Komai et al. 2002), diuretics (Girerd et al. 
1998), and BBs (Asmar et al. 2001; Mahmud and Feely 2008) have been shown 
to reduce arterial stiffness, although these effects have been thought to be 
largely BP-dependent.  
Although AIx is considered a surrogate measure of arterial stiffness, the 
effect of antihypertensive drugs on AIx and aortic PWV is not always in the 
same direction (Kelly et al. 2001). Reduction in AIx is accomplished by the 
active effect of drugs on the muscular arteries and the passive effect on the 
elastic arteries. Vasodilating drugs (ACEIs, ARBs, CCBs, and nitrates) reduce 
pulse wave reflection and hence AIx, through their action on smooth muscle 
cells in the arterial wall (Nichols and O’Rourke 2005). Recently, the renin 
inhibitor aliskiren reduced AIx more than the ACEI ramipril despite similar BP 
reduction (Virdis et al. 2012). Diuretics have a neutral effect, while con-
ventional BBs increase pulse wave reflection (Jiang et al. 2007; Protogerou 
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et al. 2009b). However, vasodilating BBs differ from conventional BBs as they 
effectively reduce AIx (Mahmud and Feely, 2008). Several haemodynamic 
factors may contribute to this. In short-term studies nebivolol has been shown to 
significantly reduce PVR (Kamp et al. 2003), which is attributed to its endo-
thelial nitric oxide synthase (eNOS) stimulatory effects (Münzel and Gori 
2009). In addition, nebivolol reduces heart rate (Dhakam et al. 2008) and 
increases ejection duration less than atenolol (Mahmud and Feely 2008).  
 
 
2.2.3. Assessment of endothelial function  
using pulse wave analysis 
The vascular endothelium is the inner layer of blood vessels. The endothelium 
plays a key role in the biology of the arterial wall through the release of vasoac-
tive and trophic factors (Lekakis et al. 2011). Endothelial dysfunction is widely 
defined as the imbalance between vasodilating and vasoconstricting substances 
produced by endothelial cells (Deanfield et al. 2005). When this balance is 
disrupted, it predisposes the vasculature to vasoconstriction, leukocyte 
adherence, platelet activation, mitogenesis, pro-oxidation, thrombosis, impaired 
coagulation, vascular inflammation, and atherosclerosis (Verma and Anderson 
2002). The NO, which is produced in the endothelium from L-arginine by 
eNOS, is the main vasodilating and a major antiatherogenic biomolecule in the 
arteries (Davignon and Ganz 2004). The NO-mediated EDV is considered a 
hallmark of endothelial function. It is well accepted that endothelial dysfunction 
occurs in response to cardiovascular risk factors and precedes the development 
of atherosclerosis (Shimokawa 1999; Ross 1999). Endothelial dysfunction con-
tributes to hypertension, atherogenesis, and the progression of CVD (Cockcroft 
2005). In hypertensive patients endothelial dysfunction is increased (Panza et al. 
1990) and associated with cardiovascular events (Perticone et al. 2001). Fur-
thermore, a study in postmenopausal hypertensive women has shown that a 
change in endothelial function with antihypertensive treatment predicts cardio-
vascular outcome (Modena et al. 2002). 
A variety of methods have been developed for assessment of endothelial 
function (Lekakis et al. 2011; Lind et al. 2011). Originally, endothelial function 
was assessed as the vasomotor response to acetylcholine (which stimulates NO 
release) in a coronary artery (Ludmer et al. 1986). However, the invasiveness of 
this method restricts its use in clinical trials. A number of less invasive tech-
niques have since been developed for EDV assessment. Venous occlusion 
plethysmography evaluates EDV in the the resistance arteries of the forearm. 
Another widely used method, ultrasound-based flow-mediated dilation, eva-
luates EDV in the conduit arteries (Lekakis et al. 2011). 
Recently, PWA with pharmacologic tests has emerged as a simple, non-
invasive, and reproducible method for assessment of endothelial function 
(Wilkinson et al. 2002a). The advantage of assessment of endothelial function 
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with the use of PWA is that it embraces global endothelial function, i.e. both the 
conduit and resistance vessels (McEniery et al. 2006). Changes in small artery 
tone affect pulse wave reflection: vasodilation reduces AIx, whereas 
vasoconstriction increases it (Nichols et al. 2008; Lekakis et al. 2011). The 
GTN, a NO donor, directly induces vasodilation (Kelly et al. 1990), thus 
reducing pulse wave reflections. The observation that acetylcholine, which 
stimulates the release of NO by the endothelium, reduces pulse wave reflection 
in vivo (Klemsdal et al. 1994) led to the proposition by Chowienczyk et al. 
(1999) that endothelial function could be measured using PWA with 
pharmacological tests. Augmentation index corrected for heart rate 75 beats/min 
(AIx@75) is measured at baseline and after the administration of an inhalable 
beta-2 agonist (i.e. salbutamol) and a NO donor (i.e. GTN). The effects of these 
drugs on AIx correspond to endothelium-dependent and -independent 
vasodilation, respectively.  
Endothelial function assessed by using PWA with the administration of 
salbutamol and GTN correlates well with the response to acetylcholine and 
sodium nitroprusside in the forearm vascular bed (Wilkinson et al. 2002a). This 
response is assessed using venous occlusion plethysmography, which is 
currently considered the gold standard for assessment of endothelial function 
(Lind et al. 2011). Given the novelty of the technique, relatively few clinical 
trials have used PWA with a pharmacological test to assess EDV. However, to 
date reduced EDV, assessed using PWA with pharmacological tests, has been 
shown in diabetes (Chowienczyk et al. 1999), hypercholesterolaemia (Wilkin-
son et al. 2002a), coronary artery disease (Hayward et al. 2002), peripheral 
artery disease (Kals et al. 2006), and rheumatoid arthritis (Wållberg-Jonsson 
et al. 2008). 
 
 
2.3. Additional subclinical markers  
for target organ damage 
Only a small fraction of hypertensive patients have an elevation of BP alone, 
with the great majority exhibiting additional cardiovascular risk factors, sub-
clinical target organ damage, or CVD (Mancia et al. 2007). Furthermore, when 
concomitantly present, these factors potentiate each other, leading to a total car-
diovascular risk which is greater than the sum of its individual components. 
Thus, assessment of subclinical target organ damage is considered to be an 
important component of cardiovascular risk assessment in hypertensive patients 
(Mancia et al. 2009). Currently, organ damage assessment of the heart, the 
blood vessels, and the kidneys is recommended in hypertensive patients by the 
ESH/ESC hypertension guidelines (Mancia et al. 2007).  
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2.3.1. Carotid artery intima-media thickness 
Pignoli et al. (1986) validated the concept that carotid IMT as measured by  
B-mode ultrasound and applied either in vitro or in situ at the time of autopsy, 
reflected direct measurements of aortic and/or carotid specimens. Based on this 
data, carotid IMT is considered a direct measure of the status of the vascular 
wall, and abnormalities are not a surrogate but a direct measure of athero-
sclerotic and arteriosclerotic processes (Mancini et al. 2004). Carotid IMT using 
ultrasound is a quick, non-invasive, relatively inexpensive, and easily available 
method for subclinical target organ damage assessment (Mancia et al. 2007). 
The ESH and ESC have established carotid IMT >0.9 mm or a plaque as a 
marker for subclinical target organ damage (Mancia et al. 2007). Ultrasound 
scannings limited to the common carotid arteries are likely to measure vascular 
hypertrophy only (arteriosclerosis), whereas assessment of atherosclerosis also 
requires scanning of the bifurcations and/or internal carotids where plaques are 
more frequent (Mancia et al. 2007). Despite the lesser atherosclerotic involve-
ment of the common carotid artery, it has increasingly become the site of choice 
for measurement of carotid IMT. This is mainly because assessment and quanti-
fication of IMT in the internal carotids and carotid bifurcations are far more 
difficult for various technical and methodological reasons (Espeland et al. 
1999).  
Traditional risk factors such as male sex, ageing, being overweight, elevated 
BP, diabetes, and smoking are positively associated with carotid IMT in epi-
demiological and observational studies (O’Leary et al. 1999; Chambless et al. 
2002; Van der Meer et al. 2003). Additionally, novel cardiovascular risk fac-
tors, such as C-reactive protein (CRP), oxidized low-density lipoprotein 
(oxLDL), and plasma viscosity have been shown to be associated with carotid 
IMT (Lee et al. 1998; Van der Meer et al. 2002; Kampus et al. 2007). Increased 
carotid IMT correlates with calcific coronary disease as detected by computed 
tomography (Davis et al. 1999). 
Several studies have confirmed that carotid IMT is associated with 
cardiovascular events and diseases (Craven et al. 1990; Salonen and Salonen 
1991; Chambless et al. 1997; O’Leary et al. 1999; Chambless et al. 2000). A 
recent meta-analysis including 37 197 subjects with a mean follow-up of 5.5 
years demonstrated that for an absolute carotid IMT difference of 0.1 mm, the 
future risk of myocardial infarction increases by 10% to 15%, and the stroke 
risk increases by 13% to 18% (Lorenz et al. 2007). Furthermore, carotid IMT 
has proved to be a valuable marker for therapeutic benefit in clinical trials. A  
4-year study in hypertensive patients showed that despite similar clinic BP 
reduction, lacidipine was superior to atenolol in slowing down carotid IMT 
progression (Zanchetti et al. 2002). These data were confirmed in a recent meta-
analysis which showed that in high risk patients ACEIs, BBs, and CCBs reduce 
the rate of carotid IMT progression compared to placebo or no-treatment (Wang 
et al. 2006). Meanwhile, in the actively-controlled trials CCBs reduced the 
progression of carotid IMT more than diuretics, BBs, or ACEIs. However, 
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whether a decrease of IMT progression is associated with a reduction in 
cardiovascular events and an improvement in prognosis has not been 
demonstrated (Zanchetti et al. 2009). 
 
 
2.3.2. Left ventricular thickness 
The LVH is initially a compensatory effect in hypertension, which represents 
adaptation to increased heart afterload. However, this is the first step towards 
the development of overt clinical disease (Agabiti Rosei and Muiesan 2011). 
The prevalence of LVH increases with age, which might reflect the influence 
that additional risk factors exert over time (Agabiti-Rosei et al. 2007b). 
Assessing LVH markedly improves the risk stratification in hypertensive 
patients without evidence of target organ damage after routine examination 
(Cuspidi et al. 2002). The LVH can be assessed using echocardiography or 
electrocardiography (ECG). However, left ventricular mass index measured 
using echocardiography is more sensitive than ECG in diagnosing LVH (Rei-
chek and Devereux 1981) and in predicting cardiovascular risk (Levy et al. 
1990). According to ESH and ESC recommendations (Mancia et al. 2007), the 
assessment of left ventricular mass should include measurements of the inter-
ventricular septum, left ventricular posterior wall thickness, and end diastolic 
diameter. Using these parameters left ventricular mass is calculated using the 
formula recommended by the American Society of Echocardiography (Lang et 
al. 2005). Subsequently, left ventricular mass is indexed by body height or body 
surface area (de Simone et al. 1992).  
The LVH is an independent cardiovascular risk factor in the general popu-
lation (Levy et al. 1990) and in patients with hypertension (Koren et al. 1991), 
end-stage renal disease (Foley et al. 1995), and coronary artery disease (Ghali et 
al. 1992). A number of studies have shown that reducing LVH with 
antihypertensive therapy improves cardiovascular outcome (Muiesan et al. 
1995; Verdecchia et al. 1998; Koren et al. 2002). However, the relationship 
between echocardiographic left ventricular mass and clinical BP is usually weak 
(Devereux et al. 2004). Moreover, a large body of evidence indicates that there 
is no significant or weak correlation between reduction in left ventricular mass 
and decrease in brachial BP (Mancia et al. 1997; Devereux et al. 2004, Gosse et 
al. 2000). Most recently, the LIFE study demonstrated that atenolol was inferior 
to losartan in reducing LVH despite the fact that both drugs reduced brachial BP 
to a similar degree (Devereux et al. 2004). Left ventricle afterload, the main 
determinant of LVH, is affected more by central than peripheral haemo-
dynamics (Hashimoto et al. 2007). These changes in central haemodynamics are 
sensed by the heart as measured with the use of plasma brain natriuretic protein 
(Deary et al. 2002). Indeed, compared with brachial BP, central BP is a stronger 
determinant of LVH (Roman et al. 2007). With conventional BB therapy (e.g. 
atenolol) pulse wave reflection in the arterial tree increases, thus augmenting 
left ventricular afterload, and compromising normal ventricular relaxation and 
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coronary filling (de Luca et al. 2004). The results of a recent meta-analysis 
(Fagard et al. 2009) are in accordance with previous evidence (Klingbeil et al. 
2003) that BBs yield less regression of left ventricular mass compared to other 
antihypertensive drugs. However, the majority of the 31 reviewed studies where 
BBs were used involved atenolol. There are scarce and only short-term data 
(Liu et al. 1999; Fountoulaki et al. 2005) about vasodilating BBs, e.g. 
nebivolol, which have a beneficial effect on pulse wave reflection (Mahmud and 
Feely, 2008).  
 
 
2.4. Biochemical markers for oxidative stress, 
inflammation and endothelial function 
Although several traditional risk factors are known in hypertension, they do not 
fully explain cardiovascular risk in these patients. Biomarkers are generally 
considered to be molecules, proteins, or enzymes in body fluids that provide an 
independent diagnostic or prognostic value by reflecting an underlying disease 
state or condition (Tsimikas et al. 2006). Although firmly inter-related (Liao et 
al. 1994), biomarkers for inflammation, OxS, and endothelial dysfunction, stand 
as important novel markers of cardiovascular risk. Hence, general aspects of 
these three classes of markers are reviewed below. 
 
 
2.4.1. Oxidative stress 
Metabolism of oxygen by cells generates potentially deleterious reactive spe-
cies, also including reactive oxygen species (Zilmer et al. 2010). Living 
organisms have evolved a network of antioxidant defence mechanisms to 
maintain their survival against abnormal levels of OxS (Dhalla et al. 2000). 
High-grade OxS results from the imbalance between the generation of reactive 
oxygen species and the antioxidant defence systems. In experimental studies 
OxS has been shown to induce hypertension (Touyz 2004). Indeed, OxS is 
increased in essential hypertension (Russo et al. 1998). Many mechanisms may 
contribute to the generation and/or maintenance of hypertension by high-grade 
OxS, including the generation of vasoconstrictor lipid peroxidation products, 
such as isoprostanes, quenching of NO by superoxide, and overproduction of 
oxLDL (Grossman 2008).  
Isoprostanes are stereoisomers of prostaglandins that are formed primarily 
through the non-enzymatic peroxidation of arachidonic acid by reactive oxygen 
species (Morrow 2006). Isoprostanes are considered the most sensitive markers 
for lipid peroxidation and the most reliable markers for systemic OxS in the 
human body (Moore and Roberts 1998; Morrow 2005). Hence, isoprostanes 
have become the gold standard in measuring OxS in vivo (Tsimikas et al. 
2006). There are several mechanisms known to account for the hypertensive 
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effects of isoprostanes. They have potent vasoconstrictor and antinatriuretic 
effects; furthermore, isoprostanes are related to the renin-angiotensin system 
and endothelin formation (Romero et al. 1999; Ortiz et al. 2001). Elevated iso-
prostane levels have been documented in patients with hypercholesterolaemia, 
diabetes mellitus, smoking, and renovascular hypertension (Morrow 2005).  
The oxLDL is generated with the peroxidation of lipid and protein content of 
low-density lipoprotein (LDL). Oxidation of LDL occurs primarily in the vessel 
wall, which activates several inflammatory and atherogenic pathways (Navab et 
al. 2004). The oxLDL is not present in normal arteries. However, it is present in 
almost all types of atherosclerotic lesions (Tsimikas et al. 2006). It has been 
shown that oxLDL but not native LDL is recognised by scavenger receptors and 
taken up by macrophages, a pivotal process in the development of athero-
sclerosis (Steinberg et al. 1989). This suggests that plasma levels of oxLDL are 
influenced mainly by the degree of local OxS in the arterial wall and suscep-
tibility of LDL to oxidation (Tsimikas et al. 2006). The oxLDL increases the 
synthesis of caveolin-1, which inhibits the production of NO by inactivating 
eNOS (Kinlay et al. 2001). Indeed, coronary and brachial endothelial function is 
strongly correlated with oxLDL levels (Penny et al. 2001; Matsumoto et al. 
2004). The oxLDL is a valuable marker for subclinical atherosclerosis (Kampus 
et al. 2007; Lind et al. 2008) and is related to severity of the acute coronary 
syndrome (Ehara et al. 2001).  
The OxS contributes to target organ damage and CVD (Heitzer et al. 2001, 
Ehara et al. 2001). Thus, reversal of OxS could represent an adjunctive target 
for antihypertensive treatment. Although large studies have shown that anti-
oxidant supplementation does not lower BP (Heart Protection Study Collabo-
rative Group 2002; Kim et al. 2002), it improves endothelial dysfunction in 
patients with hypertension (Taddei et al. 1998), coronary artery disease (Title et 
al. 2000), and cardiovascular risk factors (Heitzer et al. 1996; Ting et al. 1997). 
Several studies have demonstrated that antihypertensive therapy with ACEIs, 
ARBs, and CCBs reduces OxS (Ghiadoni et al. 2003; Taddei et al. 2003; Sáez 
et al. 2004; Muda et al. 2006). However, the data about the effect of BBs on 
OxS is controversial. There is emerging evidence that vasodilating BBs (e.g. 
nebivolol) have superior antioxidative effects compared to conventional BBs 
(Fratta Pasini et al. 2005; Celik et al. 2006). The majority of studies investi-
gating the effect of antihypertensive treatment on OxS have been of short-to-
mid-term duration. However, the short-term effects of drugs on OxS may not 
reflect their effect during long-term antihypertensive therapy (Sáez et al. 2004). 
  
 
2.4.2. Endothelial dysfunction 
A healthy endothelium is responsible for NO production from its precursor,  
L-arginine, by eNOS. L-arginine is metabolised in vivo by a class of enzymes 
known as the protein arginine methyltransferases (Khan et al. 2007). The main 
products of these reactions are symmetric dimethylarginine, asymmetric 
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dimethylarginine (ADMA), and NG-monomethyl L-arginine. The latter two 
have been shown to inhibit eNOS; with ADMA having higher concentrations in 
the body, it is considered the primary inhibitor of eNOS activity (Vallance et al. 
1992). The ADMA competitively inhibits NO elaboration by displacing  
L-arginine from eNOS (Vallance et al. 1992). It has been suggested that, in 
addition to its direct eNOS inhibitory effect, ADMA activates the renin-
angiotensin system and released angiotensin II activates nicotinamide adenine 
dinucleotide phosphate-oxidase. Subsequently, superoxide is produced which 
reduces the bioavailability of NO (Veresh et al. 2008). The ADMA is mainly 
metabolised by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) 
into L-citrulline and dimethylamine, and is additionally eliminated by the 
kidneys (Martens-Lobenhoffer and Bode-Böger 2006). Dysfunction of the  
L-arginine/NO pathway is a common mechanism by which several cardio-
vascular risk factors mediate their deleterious effects on the vascular wall 
(Böger 2005). Furthermore, recent data suggest that ADMA may act as a link 
between subclinical inflammation and endothelial dysfunction (Antoniades et 
al. 2011).  
The ADMA is closely related to endothelial dysfunction measured by using 
venous occlusion plethysmography (Perticone et al. 2005) and flow-mediated 
dilation (Juonala et al. 2007), as well as by the coronary flow reserve (Takiuchi 
et al. 2004). Hence, numerous studies have used ADMA as a single surrogate 
for endothelial dysfunction in different conditions (Weber et al. 2007). The 
ADMA has been shown to be increased in the presence of other cardiovascular 
risk factors and several disease states. These cardiovascular risk factors include 
hypercholesterolaemia (Böger et al. 1998), hypertriglyceridaemia (Lundman et 
al. 2001), previous gestational diabetes (Mittermayer et al. 2002), insulin 
resistance (Stühlinger et al. 2002), increased carotid IMT (Miyazaki et al. 1999; 
Zoccali et al. 2002; Chirinos et al. 2008), and non-traditional risk factors such 
as CRP (Zoccali et al. 2002) and vascular cellular adhesion molecules 
(Nanayakkara et al. 2005). Clinical conditions that are associated with increased 
ADMA concentrations include hypertension (Perticone et al. 2005), syndrome 
X (angina pectoris with normal coronary arteriograms) (Piatti et al. 2003), 
diabetes mellitus (Lin et al. 2002), peripheral artery disease (Böger et al. 1997), 
pulmonary hypertension (Gorenflo et al. 2001), preeclampsia (Savvidou et al. 
2003), chronic heart failure (Kielstein et al. 2003), ischaemic stroke (Yoo et al. 
2001), and cerebral small vessel disease (Khan et al. 2007). In patients with 
chronic kidney disease, plasma ADMA is inversely related to eGFR and 
represents a strong and independent risk marker for progression to end-stage 
renal disease and mortality (Ravani et al. 2005). Furthermore, ADMA predicts 
all-cause mortality in healthy subjects (Böger et al. 2009) and cardiovascular 
events in patients with coronary artery disease (Lu et al. 2003; Schnabel et al. 
2005), end-stage renal disease (Zoccali et al. 2001), and peripheral artery 
disease (Mittermayer et al. 2006).  
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Various pharmacological agents such as antidiabetic drugs (Stühlinger et al. 
2002) and oestrogen replacement therapy (Teerlink et al. 2003) have been 
shown to reduce ADMA levels. Regarding antihypertensive drugs, ARBs 
(telmisartan, losartan, eprosartan) and ACEIs (perindopril, enalapril) have been 
shown to effectively reduce ADMA levels (Ito et al. 2001; Delles et al. 2002; 
Scalera et al. 2008). Data about BBs are intriguing. Conventional BBs such as 
bisoprolol, atenolol, and metoprolol have no effect on ADMA level or even 
increase it (Ito et al. 2001; Oğuz et al. 2007; Pasini et al. 2008). The vaso-
dilating BB nebivolol has been shown to stimulate NO release in endothelial 
cells (Cominacini et al. 2003) and upregulate DDAH expression (Pasini et al. 
2008), consequently improving endothelial dysfunction in hypertensive patients 
(Cockcroft et al. 1995). However, there are controversial data about the effect 
of nebivolol on plasma ADMA levels (Oğuz et al. 2007; Pasini et al. 2008; 
Kandavar et al. 2011). 
 
 
2.4.3. Inflammation 
Recent evidence suggests that chronic low-grade inflammation has a key role in 
the pathogenesis of atherosclerosis (Ross 1999). A number of circulating 
markers of inflammation have been extensively studied regarding their cardio-
vascular effects (Verma and Anderson 2002). Amongst them, CRP has emerged 
as a robust and independent risk marker (Bisoendial et al. 2007). The CRP is 
produced by the liver, by macrophages in the atheroma, and by the smooth 
muscle cells of the arteries in response to proinflammatory cytokines, including 
interleukin-6 (IL-6) (Torzewski et al. 1998; Calabró et al. 2003). In vitro, CRP 
decreases eNOS bioactivity (Venugopal et al. 2002; Verma et al. 2002), and 
increases the expression of the endothelial receptor for oxLDL (Li et al. 2004), 
thus eliciting endothelial dysfunction. Soluble cellular adhesion molecules are 
expressed on the surface of endothelial cells and leukocytes in response to cer-
tain cardiovascular risk factors and proinflammatory cytokines (Vita et al. 
2004). They orchestrate the process of leukocyte rolling, adhesion, and trans-
migration into the subintimal space (Verma and Anderson 2002).  
It has been shown in humans that biomarkers of inflammation, such as CRP, 
IL-6, and soluble intercellular adhesion molecule-1 (sICAM-1), are associated 
with endothelial dysfunction and arterial stiffness (Van Bussel et al. 2011). 
Furthermore, CRP levels are associated with the risk of developing hyper-
tension (Sesso et al. 2003). Arterial hypertension is associated with increased 
inflammation (Preston et al. 2002; Kampus et al. 2006). The CRP has 
consistently been shown to predict cardiovascular events in high-risk patients 
(Haverkate et al. 1997; Ridker et al. 1998) and in the general population 
(Ridker et al. 2002). Furthermore, CRP may have an additional value in 
estimating cardiovascular risk in patients at intermediate risk (Wilson et al. 
2008). Although CRP has been the most extensively studied inflammatory 
marker (Albert and Ridker 2006), other markers such as sICAM-1 and IL-6 
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have been demonstrated to predict cardiovascular events (Ridker et al. 2000a; 
Ridker et al. 2000b). Elevated levels of sICAM-1 have been found in patients 
with cardiovascular risk factors and may predict the development of CVD 
(Verma and Anderson 2002).  
The CRP has been suggested as an attractive target for prevention and treat-
ment of cardiovascular events. In secondary prevention the reduction in CRP 
has been shown to result in a decreased atheroma burden and in improved car-
diovascular outcome, independently of the LDL lowering effect of statins 
(Nissen et al. 2005; Ridker et al. 2005). Antihypertensive drugs such as ARBs, 
ACEIs, and CCBs have been shown to decrease the level of sICAM-1 and CRP 
(Agabiti Rosei et al. 2005; Derosa et al. 2010) while thiazide diuretics and 
conventional BBs have no or small effect (Touyz et al. 2007; Martinez-Martin 
et al. 2011).  
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3. AIMS OF THE THESIS 
The general aim of the current thesis was to assess the biochemical, functional 
and structural properties of the vasculature in hypertension, as well as to inves-
tigate the effect of antihypertensive therapy on these parameters. 
 
The specific aims of the present thesis were the following: 
1. To investigate the relationship between asymmetric dimethylarginine, 
carotid intima-media thickness, and endothelial function in hypertensive 
patients. 
2. To determine the long-term effects of the beta-blockers nebivolol and 
metoprolol succinate on central blood pressure, arterial stiffness, and left 
ventricular wall thickness. 
3. To investigate the association between reduction in central blood pressure 
and reduction in left ventricular wall thickness in long-term antihyper-
tensive therapy. 
4. To compare the long-term effects of nebivolol and metoprolol succinate on 
oxidative stress and inflammation in hypertension. 
5. To study the importance of the underlying haemodynamic abnormality on 
the response to antihypertensive treatment with an alpha-blocker (doxa-
zosin), a beta-blocker (bisoprolol), an angiotensin II receptor blocker (can-
desartan), and a nitrate (isosorbide mononitrate). 
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4. SUBJECTS AND METHODS 
4.1. Study subjects 
Two groups of patients with essential hypertension were recruited.  
The first group of patients (n=80) (Papers I–III) were recruited from general 
practitioners’ offices in the South-Estonian region. Newly diagnosed treatment-
naïve patients with mild-to-moderate essential hypertension, aged 30 to 65 
years, were recruited between March 2006 and December 2009. All patients 
were studied in the Department of Cardiology, University of Tartu. Mild or 
moderate hypertension was defined as seated systolic BP 140 to 179 mmHg 
and/or diastolic BP 90 to 109 mmHg on ≥ 2 occasions separated by 1 month. 
Patients were excluded during the screening period in case they had diabetes 
mellitus; body mass index (BMI) > 30 kg/m2; coronary artery disease; clinically 
relevant heart failure (New York Heart Association class II–IV); renal failure; 
chronic pulmonary disease; valve disease; arrhythmias; secondary hypertension; 
clinically relevant atherosclerotic disease of the lower extremities; acute or 
chronic inflammatory disease; hypercholesterolaemia; known hypersensitivity 
or allergic reaction to BBs; pregnancy or breastfeeding; history of hepatic, 
renal, metabolic, or endocrine diseases; heavy smoking (> 10 cigarettes a day); 
and excessive alcohol consumption. 
The second group of patients (Paper IV) consisted of newly diagnosed 
treatment-naïve hypertensive patients (n=53) of both sexes aged 18–80 years. 
Forty-one patients were studied in the Department of Cardiology, University of 
Tartu, Tartu, Estonia. Twelve patients were studied in the Clinical Pharma-
cology Unit, University of Cambridge, Cambridge, UK. Patients were recruited 
from local hypertension outpatient clinics and from general practitioners’ 
offices. We excluded patients with secondary hypertension, uncontrolled 
hypertension (brachial BP > 200/100 mmHg), and pregnant or nursing women 
and women of childbearing age not taking contraceptives. Additionally, patients 
with gout, asthma, heart failure (New York Heart Association class III–IV), 
liver failure (defined as an elevation of alanine aminotransferase four times 
above upper limit of normal), renal failure (chronic kidney disease stage 3 or 4), 
and terminal illnesses (e.g. cancer), were excluded.  
 
 
4.2. Methods 
4.2.1. Study protocol 
Papers I–III: This was a parallel-group, randomised, double-blind, active 
controlled, one-centre phase IV study. All patients who met the inclusion and 
exclusion criteria were assigned a patient number in the ascending order. This 
number determined whether treatment was to be performed with nebivolol or 
metoprolol. Randomisation was performed in blocks of four. Patients were 
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randomly assigned to receive either nebivolol (Nebilet, dL-nebivolol hydro-
chloride, Berlin-Chemie AG, Germany) or metoprolol (Betaloc Zok, metoprolol 
succinate, AstraZeneca, UK). The allocation of patients into treatment arms 
remained unknown for all patients throughout the study. All nebivolol and 
metoprolol tablets were encapsulated in identical form, size, colour, and shape 
by an accredited pharmacy manufacturing unit. The nebivolol-treated patients 
received 5 mg of the drug daily, and the metoprolol-treated patients started with 
50 mg of the drug daily with possible up-titration to 100 mg daily 2 weeks after 
randomisation. If the target BP of < 140/90 mmHg was not achieved, the inves-
tigator was free to add 12.5 to 25 mg of hydrochlorothiazide (Hypothiazid; 
Chinoin Pharmaceuticals and Chemical Works Private Co. Ltd., Hungary) daily 
4 weeks after randomisation. The duration of the study was 52 weeks plus the 
screening period of 2 weeks. The patients attended follow-up visits at weeks 2, 
4, 12, 24, 40, and 52.  
Paper IV: This was a crossover, randomised, double-blind, placebo-
controlled two-centre phase IV study. The study involved 4 different anti-
hypertensive drugs and the drug dosages were gradually force titrated. Standard 
Latin square randomisation in 1 block was used. All drugs and the placebo were 
encapsulated to look identical by Ipswich Hospital Pharmacy, Ipswich, UK. We 
used candesartan (Amias, candesartan cilexetil, Takeda UK Ltd., UK) 8 mg for 
1 week and thereafter 16 mg; bisoprolol (Cardicor, bisoprolol fumarate, Merck 
Pharmaceuticals, UK) 2.5 mg for 1 week and thereafter 5 mg; isosorbide 
mononitrate (ISMN) (Elantan, isosorbide-5-mononitrate, Schwarz Pharma Ltd., 
UK) 25 mg for 1 week and thereafter 50 mg; doxazosin (Cardura, doxazosin 
mesilate, Pfizer Ltd., UK) 1 mg for 1 week, 2 mg for the 2nd week and there-
after 4 mg; and the placebo. All drugs were administered once a day. Each 
treatment phase lasted for 6 weeks after which the patient was switched to the 
next treatment phase. There were no wash-in or wash-out periods. Thus, each 
patient remained in the study for up to 30 weeks. 
  
 
4.2.2. Brachial blood pressure measurement 
In Papers I–III, brachial BP was measured in a sitting position from the non-
dominant arm as a mean of three consecutive measurements at five-minute 
intervals using a validated oscillometric technique (OMRON M4-I, Omron 
Healthcare Europe BV, the Netherlands). The mean of all (Paper I) or the two 
closest (Paper II and III) BP readings was used in further analysis. Brachial PP 
was calculated as the difference between brachial systolic BP and diastolic BP. 
In Paper IV, triplicate supine BP measurements from the dominant arm were 
used (OMRON HEM-705CP, Omron Corporation, Japan) with a mean of the 
two closest BP readings used in the analysis. 
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4.2.3. Assessment of aortic pulse wave velocity 
Aortic PWV was determined by sequential acquisition of pulse waveforms from 
the carotid and femoral arteries (SphygmoCor Px, version 7.1, AtCor Medical, 
Australia) using the Millar tonometer (SPT-301B, Millar Instruments, USA). 
The timing of these waveforms was compared with that of the R wave on a 
simultaneously recorded ECG. Aortic PWV was determined by calculation of 
the difference between the carotid and the femoral path lengths divided by the 
difference in the R wave to waveform foot times. Path length for the determi-
nation of aortic PWV was measured as the surface distance between the 
suprasternal notch and the femoral site minus the distance between the 
suprasternal notch and the carotid site using a tape measure. In Paper IV, aortic 
PWV was adjusted to MAP. All aortic PWV measurements were made in dupli-
cate, and their mean values were used in subsequent analysis. Aortic PWV 
measurements were performed by 2 observers and the intra- and inter-observer 
coefficents of variation have been published previously (Zagura et al. 2012). 
 
 
4.2.4. Pulse wave analysis 
Radial artery waveforms were recorded with a high-fidelity micromanometer 
(applanation tonometry) from the wrist of the dominant arm, and PWA was per-
formed of the systolic portion (SphygmoCor Px, version 7.1, AtCor Medical, 
Australia) of the pulse curve in accordance with established guidelines (Laurent 
et al. 2006). The corresponding ascending aortic waveforms were then 
generated, using a validated transfer function, from which central systolic and 
diastolic BP, central PP, and AIx were calculated. The AIx was defined as the 
difference between the second and the first systolic peaks of the central arterial 
waveform, expressed as a percentage of central PP (Laurent et al. 2006). In 
Paper IV, AIx was adjusted to heart rate and MAP. Timing of the reflected 
waveform (Tr) was the time from the beginning upstroke of the derived aortic 
systolic pulse waveform to the inflection point. The MAP was calculated from 
the integration of the radial artery waveform. The degree of PPA was calculated 
as brachial PP divided by central PP. In Papers I-III the PWA measurements 
were made in duplicate, and the mean values were used in subsequent analysis. 
In Paper IV the PWA measurements were made in triplicate, and the means of 
the 2 closest readings were used in further analysis. The PWA measurements 
were performed by 2 observers and the intra- and inter-observer coefficents of 
variation for AIx@75 have been published previously (Zagura et al. 2012). 
 
 
4.2.5. Assessment of endothelial function 
Measurements of PWA were performed at baseline (two recordings), and at 
every five minutes for twenty five minutes after 400 μg of salbutamol inhalation 
with a spacer (Ventolin, salbutamol sulphate, GlaxoSmithKline, France). After 
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that, a 500-μg tablet of GTN (Nitroglycerin Nycomed, GTN, Nycomed, 
Denmark) was placed under the tongue for three minutes and AIx@75 was 
measured at every three to five minutes for twenty minutes. The greatest 
difference from baseline AIx@75 with both pharmacological interventions was 
used to assess EDV and endothelium-independent vasodilation, respectively 
(Wilkinson et al. 2002a; Kals et al. 2006). 
 
 
4.2.6. Ultrasound examination  
of carotid artery intima-media thickness 
The IMT scans of the common carotid artery were performed by a specialist 
using an ultrasound device (Sonos 7500, Philips Medical Systems, Inc., USA) 
with a 12-MHz transducer and videotaped on a super-Video Home System 
videocassette recorder for further analysis. Longitudinal images of distal one cm 
of the left and right common carotid arteries at the far wall and near wall were 
measured in three projections (anterolateral, lateral, and posterolateral). The 
scans were measured with the Prosound software (Caltech, USA) by an inde-
pendent technician at the University of Eastern Finland, Kuopio, Finland. The 
mean of mean carotid IMT was defined as the average of the segmental mean 
carotid IMT values (Papers I and II). The mean of maximum carotid IMT was 
defined as the average of the segmental maximum carotid IMT values (Paper II) 
(Stein et al. 2008). 
 
 
4.2.7. Echocardiography 
Echocardiographic examination was performed by two experienced sono-
graphers, who were blinded to patient characteristics, using a commercially 
available device (Sonos 7500, Philips Medical Systems, Inc., USA) with a  
3.5-MHz transducer and digital recording capabilities. The images were stored 
digitally, coded with a random number, and read by two blinded observers. 
Using the 2D and the M-mode, long-axis measurements were obtained at the 
level distal to the mitral valve leaflets. The measurements were made according 
to the recommendations of the American Society of Echocardiography (Lang et 
al. 2005). Left ventricular mass was calculated using the following formula: 
0.8{1.04 [(left ventricular internal dimension at the end of the diastole + pos-
terior wall thickness at the end of the diastole + septal wall thickness at the end 
of the diastole)3-(left ventricular internal dimension at the end of the diastole)3]} 
+ 0.6 g. Left ventricular mass was indexed for the power of its allometric or 
growth relation to height (height in metres2.7) (de Simone et al. 1992); this 
method was used to adjust for differences in body size. Relative wall thickness 
was calculated using the formula (2 x posterior wall thickness at the end of the 
diastole)/ left ventricular internal dimension at the end of the diastole (Lang 
et al. 2005). 
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4.2.8. Inert gas re-breathing method 
The CO was assessed non-invasively using the inert gas re-breathing system 
(Innocor, Innovision, Denmark) (Paper IV). The inert gas re-breathing method 
is a simple, validated, and reproducible method of CO assessment (Agostoni et 
al. 2005; Gabrielsen et al. 2002). The Innocor system uses an oxygen-enriched 
mixture of an inert soluble gas (0.5% nitrous oxide) and an inert insoluble gas 
(0.1% sulphur hexafluoride) from a 4-litre anaesthesia bag. Subjects breathed 
the gas mixture over 20 seconds, with a breathing rate of 15/min. Concurrently, 
heart rate was continuously measured. Expired gases were sampled 
continuously and analysed by an infrared photoacoustic gas analyser. The use of 
sulphur hexafluoride allows the measurement of the volume of the lungs, valve, 
and rebreathing bag. Nitrous oxide concentration decreases during the 
rebreathing manoeuvre, with a rate proportional to pulmonary blood flow. 
Subsequently, CO was determined by the Fick principle, and stroke volume 
(SV) was calculated. The PVR was calculated as MAP divided by CO 
(McEniery et al. 2005b).  
 
 
4.2.9. Laboratory analyses 
White blood cell and red blood cell counts, haematocrit, haemoglobin, and 
platelets were estimated with a Sysmex XE 2100 autoanalyser (Sysmex Corp., 
Japan). Plasma glucose, total cholesterol, LDL, high-density lipoprotein (HDL), 
triglycerides, creatinine, and urine creatinine were determined by standard 
laboratory methods, using certified assays, in a local clinical laboratory.  
The other blood samples were centrifuged within 15 minutes of collection. 
Centrifuged blood samples and urine samples were divided to aliquots and 
stored at –70 ºC until analysis. The oxLDL levels were measured using an 
Enzyme-Linked Immunosorbent Assay (ELISA) kit (Mercodia AB, Sweden). 
The urinary content of 8-isoprostanes was analysed by a competitive ELISA 
(Cayman Chemical Co., USA). The urinary concentrations of 8-isoprostanes 
were corrected by urinary creatinine concentrations to account for differences in 
renal function. The plasma level ADMA was determined by a competitive 
ELISA using a commercially available kit (DLD Diagnostika, Germany). The 
plasma level of high-sensitivity CRP was determined by using a validated latex 
particle-enhanced immunoturbidimetric assay (Roche Diagnostics Gmbh, 
Germany). The sICAM-1 levels were measured by ELISA using a commer-
cially available kit (R&D Systems, USA). The IL-6 was analysed by the quan-
titative sandwich enzyme immunoassay technique (R&D Systems, USA). 
Fibrinogen was measured by the clotting method after Clauss using the Stago 
Compact analyser (Diagnostica Stago, France). Renal function was assessed 
using eGFR calculated with the abbreviated Modification of Diet in Renal 
Disease equation (Brosius et al. 2006). 
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4.2.10. Statistical analysis 
All data were tested for normality using the Kolmogorov-Smirnov test. 
Normally distributed data are presented as mean ± standard deviation; non-
normally distributed data are presented as the median with the interquartile 
range. The skewed data were log-transformed for analysis to improve normality. 
The EDV was defined as a maximum change in AIx@75 after salbutamol 
administration (Paper I). Correlations between the variables were examined 
using univariate linear regression and stepwise multiple regression analyses 
(Papers I, II, and III). The predictors for stepwise correlation analysis were 
selected on the basis of simple correlation analysis and from among the 
variables known or likely to be associated with the dependent variable (Papers I 
and II).  
For categorical variables, contingency tables were composed and the chi-
square test or the Fisher exact test was used to compare the distributions for the 
two randomised groups. For continuous variables, which were not normally 
distributed for ≥1 group, the Mann-Whitney U-test was used to test the 
difference between the groups. In other cases, the t-test was used to test for 
difference. 
Changes from the baseline to the endpoint were tested for difference from 
zero using the paired t-test; for continuous variables, which were not normally 
distributed ≥1 group, the Wilcoxon rank-sum test was employed (Papers II and 
III). Additional analyses with MAP adjusted OxS and inflammatory markers 
were conducted (Paper III). The 2-way ANOVA with repeated measures was 
used to test the interaction between time and drug, as well as error (drug x time) 
(Paper II).  
One-way repeated measures ANOVA with Bonferroni correction was used 
to analyse the effects of the drugs on haemodynamic parameters (Paper IV). 
Patients were divided according to the tertiles of baseline haemodynamic 
parameters (aortic PWV, AIx, PVR, CO, SV, and PPA), and thereafter patients 
in the 1st and in the 3rd tertile were compared regarding the reduction in 
brachial systolic, diastolic, and central systolic BP for each drug (Paper IV). 
The independent samples t-test was used to test for difference in BP reduction 
between the tertiles (Paper IV). The drug carry-over effect was assessed with 
treatment order as the independent variable (Paper IV). P<0.01 was considered 
significant in Bonferroni corrected analysis (Paper IV). Otherwise, significance 
was defined as two-sided p<0.05. 
Statistical analysis was performed with the Statistica software (version 8; 
Statsoft, USA) (Paper I), SAS (version 9.1, SAS Institute Inc., USA) and R 
(www.r-project.org) software (Papers II and III), and the SPSS software 
(version 18.0, SPSS Inc., USA) (Paper IV). 
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5. RESULTS 
5.1. Association between asymmetric 
dimethylarginine, carotid artery intima-media 
thickness and endothelial function (Paper I) 
The clinical characteristics of the study group are summarised in Table 1. Ten 
(12.5%) study subjects were smokers. Hormone replacement therapy was not 
used by any female patient. One female patient received oral contraceptives as 
concomitant therapy.  
The ADMA levels were significantly decreased in smokers (0.51 ± 0.12 μmol/L) 
compared with non-smokers (0.65 ± 0.17 μmol/L) (p=0.01). The ADMA was 
significantly correlated with EDV (r=–0.26; p=0.02) (Figure 2) and with mean 
of mean carotid IMT (r=0.32; p=0.007) (Figure 3). No correlation was detected 
between ADMA and AIx, aortic PWV, central and brachial BP values, or 
eGFR. Mean of mean carotid IMT was positively correlated with age (r=0.39; 
p=0.001). There was no correlation between EDV and IMT or EDV and age. A 
multiple regression model was constructed with ADMA as the dependent 
variable. Female gender, mean of mean carotid IMT, EDV, total cholesterol 
levels, and smoking status explained 30% of the variability of ADMA 
(p<0.001) (Table 2).  
 
Table 1. Baseline characteristics of the study subjects. 
Parameter Hypertension patients (n=80) 
Age, y  47 ± 10 
Weight, kg  79.5 ± 11.9 
Height, cm  172.2 ± 9.4 
BMI, kg/m2  26.7 ± 2.5 
Waist-to-hip ratio   0.89 ± 0.08 
Smokers, % 12.5 
Brachial systolic BP, mmHg  145.4 ± 11.9 
Brachial diastolic BP, mmHg  90.3 ± 7.6 
Brachial PP, mmHg  55.1 ± 10.7 
Central systolic BP, mmHg  131.4 ± 17.9 
Central diastolic BP, mmHg  84.8 ± 9 
Central PP, mmHg  46.6 ± 13.4 
Heart rate, beats/min  69 ± 9.1 
AIx, %  23.2 ± 13.4 
AIx@75, %  19.2 ± 12.8 
Tr, ms  146.8 ± 13.7 
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Table 1. Continuation 
Parameter Hypertension patients (n=80) 
Aortic PWV, m/s  7.4 ± 1.4 
Mean of mean carotid IMT, mm  0.8 ± 0.1 
Total cholesterol, mmol/L  5.3 ± 0.87 
LDL cholesterol, mmol/L  3.4 ± 0.8 
HDL cholesterol, mmol/L  1.7 ± 0.6 
Triglycerides, mmol/L 1 (0.8; 1.5) 
ADMA, μmol/L  0.6 ± 0.2 
Glucose, mmol/L  5.2 ± 0.6 
Creatinine, µmol/L  68.6 ± 12.9 
CRP, mg/L 0.9 (0.5; 2.1) 
eGFR, mL/min/1.73m2  102.8 ± 17.2 
Values are the mean ± SD or median with the interquartile range. 
 
 
 
Figure 2. Correlation between ADMA and EDV.   
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Figure 3. Correlation between ADMA and mean of mean carotid IMT. 
 
 
Table 2. Results of multiple regression analysis with ADMA as the dependent variable. 
Parameter Regression coefficient Standard error p value 
Mean of mean carotid IMT, mm 0.53 0.15 0.001 
Total cholesterol, mmol/L –0.06 0.02 0.008 
EDV, % change from baseline –0.01 0.004 0.02 
Gender (female) 0.07 0.04 0.05 
Smoking status –0.09 0.05 0.08 
R2=0.3; p<0.001. 
r=0.32
p=0.007 
M
ea
n 
of
 m
ea
n 
ca
ro
tid
 IM
T,
 m
m
 
ADMA, μmol/L 
44 
5.2. The long-term effects of nebivolol and metoprolol 
succinate on central blood pressure and left 
ventricular wall thickness (Paper II) 
The baseline characteristics of the untreated hypertensive subjects are presented 
in Table 3. Before randomisation there were no statistically significant 
differences in the demographic and clinical characteristics between the treat-
ment groups. A total of 40 patients (50%) were enrolled in the nebivolol arm 
and 40 (50%) were enrolled in the metoprolol arm. Out of the 80 patients 
enrolled, 63 (79%) completed the study. Seventeen patients were withdrawn 
from the study for various reasons: seven patients for lack of compliance (four 
in the nebivolol group and three in the metoprolol group), four patients for 
dizziness (two patients in each group), two patients for being non-respondent 
(both in the nebivolol group), two patients for bradycardia (one patient in each 
group), one patient for hyperglycaemia (in the metoprolol group), and one 
patient for anxiety (in the nebivolol group).  
Up-titration of metoprolol to 100 mg was performed for 13 patients (32%). 
During the treatment period 30 % of the patients (12 subjects) in the nebivolol 
group and 22.5 % of the patients (9 subjects) in the metoprolol group (p=0.5) 
received additionally 12.5 to 25 mg hydrochlorothiazide. 
The haemodynamic indices for each treatment group prior to and after one 
year of therapy are presented in Table 4. Brachial and central systolic or 
diastolic BP were not different for the groups at baseline. The AIx, AIx@75, 
and central PP were significantly higher in the nebivolol group at baseline. 
Both drugs significantly reduced heart rate, brachial systolic and diastolic 
BP, and MAP (Table 4), without differences between the groups (Figure 4). 
However, only the patients of the nebivolol treatment group showed 
significantly decreased brachial PP (p=0.02). The reduction in central systolic 
BP, central diastolic BP (Figure 5), and central PP was significant only in the 
nebivolol group. At the same time, these parameters did not display significant 
changes in the metoprolol group (Table 4). Mean reduction in central PP was 
6.2 mmHg in the nebivolol group and 0.3 mmHg in the metoprolol group 
(p=0.01). The PPA did not change during the treatment period in either 
treatment arm.  
The AIx@75 (22.9 ± 11.9 % to 18.6 ± 11.3 %; p=0.02) and aortic PWV  
7.5 ± 1.5 m/s to 6.8 ± 1.2 m/s; p=0.03) were significantly decreased after 6 
months of treatment only in the nebivolol group. However, no significant 
change was detected in AIx, AIx@75, or aortic PWV after the one-year treat-
ment period for either treatment group (Table 4). There was a trend for corre-
lation, but not significant, between heart rate change and AIx change for the 
whole study group (r=–0.24; p=0.06). However, the correlation was significant 
only for the nebivolol treatment arm (r=–0.40; p=0.03).  
There occurred a significant reduction in left ventricular posterior wall 
thickness, left ventricular relative wall thickness as well as a trend for reduction 
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in left ventricular septal wall thickness and indexed left ventricular mass 
compared to the baseline values only for the nebivolol group (Table 4). More-
over, changes in septal wall thickness were more significantly correlated with 
changes in central systolic BP (r=0.41; p=0.001) and with changes in central PP 
(r=0.32; p=0.01) compared with changes in brachial BP values (r=0.32; p=0.01 
and r=0.26; p=0.04, respectively) (Figure 6). Multiple regression analysis 
showed that only change in central systolic BP (p=0.009) was independently 
correlated with changes in septal wall thickness as the dependent variable but 
not with medication used, BMI, changes is MAP, or changes in heart rate 
(R2=0.2; p<0.01). Finally, no correlation was revealed between changes in 
brachial systolic BP and changes in septal wall thickness after adjustment for 
MAP in multiple regression analysis. 
 
Table 3. Baseline characteristics of the study subjects. 
Parameter Nebivolol (n=40) Metoprolol (n=40) p value 
Age, y  48.6 ± 10.5  44.4  ± 9.0 0.07 
Gender, male/female, n 20/20 21/19 0.8 
BMI, kg/m2  26.6 ± 2.7  26.8  ± 2.4 0.8 
Weight, kg  78.3 ± 12.0  80.7  ± 11.8 0.4 
Height, m  1.7 ± 0.1  1.7  ± 0.1 0.4 
Smokers, n 5 5 1 
Glucose, mmol/L  5.2 ± 0.4  5.2 ± 0.8 0.9 
Total cholesterol, mmol/L  5.3 ± 0.8  5.2  ± 0.9 0.6 
LDL cholesterol, mmol/L  3.4 ± 0.8  3.4  ± 0.9 0.9 
Triglycerides, mmol/L  1.2 ± 0.8  1.4  ± 1.1 0.4 
HDL cholesterol, mmol/L  1.8 ± 0.7  1.6  ± 0.4 0.3 
Creatinine, µmol/L  69.2 ± 13.1  68.0  ± 12.8 0.7 
CRP, mg/L 1.7 (0.6;2.3) 1.9 (0.5;2.5) 0.6 
Values are the mean ± SD, number, or median with the interquartile range. 
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Figure 4. Mean reduction in brachial systolic (top) and diastolic (bottom) BP during the 
study period. Both treatment groups display significantly reduced brachial systolic and 
diastolic BPs (p<0.001) during 52 weeks of treatment, without difference between the 
treatment arms. ■ indicates nebivolol; ●, metoprolol; S, screening period. 
 
 
 
Figure 5. Mean reduction in central systolic (top) and diastolic (bottom) BP measured 
at baseline, and at weeks 24 and 52. Only the nebivolol group displays significantly 
reduced central systolic (p<0.001) and diastolic (p=0.01) BPs after 52 weeks of treat-
ment compared with baseline values. ■ indicates nebivolol; ●, metoprolol. 
Time, weeks
Diastolic BP, mmHg 
Systolic BP, mmHg 
Central systolic BP, mmHg 
Central diastolic BP, mmHg 
Time, weeks
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Figure 6. A, Correlation between central systolic BP change and IVS thickness change 
(r=0.41; p=0.001) for the whole study group. B, Correlation between brachial systolic 
BP change and IVS thickness change (r=0.32; p=0.01) for the whole study group. 
C, Correlation between central PP change and IVS thickness change (r=0.31; p=0.01) 
for the whole study group. D, Correlation between brachial PP change and IVS 
thickness change (r=0.25; p=0.04) for the whole study group. IVS indicates inter-
ventricular septal thickness.  
 
 
5.3. The long-term effects of nebivolol and  
metoprolol succinate on oxidative stress and 
inflammation (Paper III) 
The baseline demographic and clinical characteristics of the untreated hyper-
tensive subjects are presented in Table 3. Before randomisation there were no 
statistically significant differences in the demographic and clinical charac-
teristics between the treatment groups. 
The unadjusted and MAP-adjusted data of OxS and inflammatory markers 
are presented in Table 5. At baseline there were no differences in OxS or  
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Table 5. Markers for inflammation and OxS at baseline and after 1 year of treatment. 
 Parameter Nebivolol Metoprolol p 
oxLDL, U/L   
Before  85.5 ± 33.8  88.6 ± 31.9 0.7 
After  62.0 ± 18.7  65.5 ± 29.1  
p <0.01 <0.01  
p* <0.01 <0.01  
8-isoprostanes, ng/mmol creatinine  
Before  43.0 ± 28.4  43.2 ± 34.9 0.7 
After  21.8 ± 18.6  34.4 ± 25.7  
p 0.01 0.4  
p* 0.01 0.1  
sICAM-1, ng/mL   
Before  235.7 ± 57.10  234.0 ± 57.2 0.9 
After  200.8 ± 55.90  213.1 ± 45.5  
p <0.01 <0.01  
p* <0.01 <0.01  
ADMA, μmol/L   
Before  0.6 ± 0.2  0.6 ± 0.2 0.5 
After  0.7 ± 0.2  0.6 ± 0.1  
p 0.4 0.3  
p* 0.8 0.3  
IL-6, pg/mL    
Before  1.6 ± 0.7  1.6 ± 0.9 0.9 
After  1.7 ± 1.0 . 2 ± 1.7  
p 0.8 0.8  
p* 0.7 0.7  
CRP, mg/L    
Before 1.0 (0.4; 1.7) 0.9 (0.5; 2.6) 0.3 
After 1.2 (0.7; 2.1) 1 (0.5; 3.3)  
p 1.0 0.9  
p* 0.8 0.7  
Fibrinogen, g/L   
Before  3.1 ± 0.5  2.9 ± 0.5 0.1 
After  3.1 ± 0.7  2.9 ± 0.8  
p 1.0 0.7  
p* 0.8 0.4  
White blood cell count, x 109/L)   
Before  6.1 ± 1.4  5.6 ± 1.6 0.1 
After  6.2 ± 1.3  5.9 ± 1.4  
p 0.2 0.2  
p* 0.2 0.2  
p*, p adjusted for treatment MAP. Values are the mean ± SD or median with the interquartile 
range. 
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inflammatory markers between the treatment arms. Both drugs reduced signifi-
cantly oxLDL levels (p<0.01 for both drugs). Only nebivolol reduced signifi-
cantly 8-isoprostane levels (p=0.01). Both metoprolol and nebivolol reduced 
significantly sICAM-1 levels (p<0.01 for both drugs). There were no changes in 
white blood cell count, CRP, IL-6, fibrinogen, or ADMA levels in either group. 
Adjustment to MAP did not change the statistical significance of the effects of 
the drugs on OxS and inflammatory markers. In the nebivolol group changes in 
oxLDL and 8-isoprostane levels were not correlated with change in brachial 
systolic BP, diastolic BP, or MAP. In the metoprolol group change in oxLDL 
levels was correlated with systolic BP change (r=0.45; p<0.01) and PP change 
(r=0.47; p<0.01). There were no correlations between change in sICAM-1 level 
and change in systolic and diastolic BP or MAP in either group.  
Total cholesterol, triglycerides, and glucose did not change significantly in 
either treatment group, but both drugs reduced significantly HDL cholesterol 
(p<0.01 for both drugs) (Table 6). An increase in LDL cholesterol level was 
observed only in the metoprolol group (p=0.02).  
 
 
Table 6. Comparison of the basic biochemical parameters between the treatment 
groups. 
   Parameter Nebivolol Metoprolol p 
Total cholesterol, mmol/L   
Before 5.3 ± 0.8 5.2 ± 0.8 0.6 
After 5.3 ± 1.0 5.4 ± 1.0  
p 0.9 0.2  
LDL cholesterol, mmol/L   
Before 3.4 ± 0.8 3.5 ± 0.8 0.9 
After 3.5 ± 1.0 3.8 ± 1.0  
p 0.9 0.02  
HDL cholesterol, mmol/L   
Before 1.7 ± 0.4 1.6 ± 0.4 0.2 
After 1.5 ± 0.4 1.4 ± 0.4  
p < 0.01 < 0.01  
Triglycerides, mmol/L   
Before 1.2 ± 0.8 1.4 ± 1.1 0.4 
After 1.4 ± 1.2 1.3 ± 0.7  
p 0.08 0.4  
Glucose, mmol/L   
Before 5.2 ± 0.5 5.2 ± 0.8 0.9 
After 5.3 ± 0.6 5.3 ± 0.8  
p 0.23 0.42  
Values are the mean ± SD. 
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5.4. Augmentation index as an underlying 
haemodynamic abnormality and the efficacy  
of antihypertensive therapy (Paper IV) 
The descriptive characteristics of the study subjects are summarised in Table 
7. In total, 53 patients (41 patients, Tartu, Estonia; 12 patients, Cambridge, UK) 
completed the study. 
The haemodynamic indices after placebo and all active drugs are shown in 
Table 8. All drugs significantly reduced brachial, and central BP, and MAP. 
However, candesartan reduced brachial and central systolic BP and PP the most. 
All drugs except bisoprolol increased PPA (p<0.001). Aortic PWV corrected to 
MAP did not change with any drug. The AIx corrected to MAP and heart rate was 
reduced by all drugs except bisoprolol, with ISMN having the relatively largest 
effect (Δ for ISMN: –5.4%) (p<0.001). The CO increased with doxazosin  
(Δ: +0.4 L/min) and was not affected by the other drugs (p<0.001). Bisoprolol 
(Δ: +14.4 mL) and doxazosin (Δ: +7.3 mL) significantly increased SV, while 
ISMN (Δ: –5.2 mL) reduced it (p<0.001). Doxazosin, candesartan, and bisoprolol 
significantly decreased PVR (p<0.001). There was no drug carry-over effect. 
Comparison of the 1st and 3rd tertiles of the baseline haemodynamic 
parameters revealed baseline AIx and PPA as determinants of BP reduction. 
The patients in the highest tertile of baseline AIx (AIx value: 36.3–48.2%), 
comprising mainly women, were significantly older, shorter, and more hyper-
tensive than the patients in the lowest tertile (AIx value: 1.7–28.9%) (Table 9). 
There was a significant difference in BP change between the tertiles of AIx for 
all drugs except ISMN (Figure 7). With candesartan, reduction in brachial and 
central systolic BP was the largest, regardless of the baseline AIx tertile. 
Bisoprolol was relatively weak at reducing brachial and central BP in the 1st 
tertile of AIx. However, in the 3rd tertile the BP lowering effect of bisoprolol (Δ 
brachial systolic BP: –23.4 mmHg) was roughly comparable to that of doxa-
zosin (Δ brachial systolic BP: –22.3 mmHg) and candesartan (Δ brachial 
systolic BP: –26.4 mmHg).  
The patients in the highest tertile of PPA (baseline PPA value: 1.22–1.87) 
comprising mainly men, were significantly younger, taller, less hypertensive and 
had lower AIx and heart rate than the patients in the lowest tertile of PPA 
(baseline PPA value: 1.05–1.11) (Table 10). There was a significant difference in 
BP change between the tertiles of PPA for all drugs except candesartan (Figure 
8). However, candesartan reduced brachial and central BP significantly more than 
the other drugs, irrespective of the tertile of baseline PPA. With bisoprolol, the 
reduction in brachial and central systolic BP was more significant in patients with 
low baseline PPA (Δ brachial systolic BP: –23.1 mmHg and Δ central systolic 
BP: –21.1 mmHg) compared to patients with high baseline PPA (Δ brachial 
systolic BP: –11.1 mmHg and Δ central systolic BP: –7.7 mmHg) (p<0.05). 
Comparison of the 1st and 3rd tertiles of baseline SV, CO, aortic PWV, or PVR 
revealed no significant differences in the BP change with the study drugs.  
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Table 7. Baseline characteristics of the study subjects. 
Parameter Hypertensive patients (n=53) 
Age, y  54.5 ± 12.1 
Sex, n 25 M / 28 F 
Height, cm  168.3 ± 8.5 
Weight, kg   81.7 ± 13.1 
BMI, kg/m2  28.8 ± 4.1 
Brachial systolic BP, mmHg  151.3 ± 18.6 
Brachial diastolic BP, mmHg  89.7 ± 9.7 
Brachial PP, mmHg  61.6 ± 15 
Central systolic BP, mmHg  142.8 ± 18.9 
Central diastolic BP, mmHg  90.8 ± 9.8 
Central PP, mmHg  52 ± 14.7 
MAP, mmHg  112.8 ± 12.4 
PPA  1.21 ± 0.17 
AIx, %  31.5 ± 6.2 
Heart rate, beats/min  63.2 ± 9.4 
Aortic PWV, m/s  8.9 ± 3 
CO, L/min  6.0 ± 1.7 
SV, mL  81.2 ± 20.2 
PVR, dyne/s  20.1 ± 5.2 
Glucose, mmol/L  5.3 ± 0.6 
Total cholesterol, mmol/L  5.6 ± 1 
HDL cholesterol, mmol/L  1.4 ± 0.5 
LDL cholesterol, mmol/L  3.8 ± 1 
Triglycerides, mmol/L  1.5 ± 0.8 
Values are the mean ± SD or number. 
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Table 9. Subject characteristics at baseline according to the tertiles of baseline AIx. 
 Tertiles of AIx, % 
 First (1.7–28.9) Third (36.3–48.2)  
Parameter (n=17) (n=18) p value 
Age, y  49.1 ± 14.1  58.1 ± 9.6 <0.05 
Males, % 15 (88.2) 4 (22) <0.001 
Weight, kg  86.9 ± 13.5  78.2 ± 6.9 <0.05 
Height, cm  176.5 ± 6.7  163.9 ± 6.1 <0.001 
BMI, kg/m2  27.9 ± 3.6  29.2 ± 2.9 0.3 
Aortic PWV, m/s  8.1 ± 1.4  8.7 ± 1.6 0.3 
Brachial SBP, mmHg  146.9 ± 17  162.4 ± 20.9 <0.05 
Brachial DBP, mmHg  86.9 ± 8.3  95.7 ± 10.0 <0.01 
Heart rate, beats/min  62.1 ± 9.7  64.0 ± 10.8 0.6 
MAP, mmHg  107.5 ± 10.3  122.9 ± 12.8 <0.001 
DBP indicates diastolic blood pressure; SBP, systolic blood pressure. Values are the mean ± SD 
or number (%). 
 
 
Table 10. Subject characteristics at baseline according to the tertiles of baseline PPA.  
 Tertiles of PPA 
 First (1.05–1.11) Third (1.22–1.87) p value 
Parameter (n=17) (n=18)  
Age, y  57.4 ± 9.3  47.5 ± 12.7 0.01 
Males, % 4 (24) 15 (83) 0.001 
Weight, kg  78.9 ± 11.3  86.1 ± 13.6 0.1 
Height, cm  162.7 ± 6.4  174.0 ± 8.1 <0.001 
BMI, kg/m2  29.8 ± 3.9  28.4 ± 3.6 0.3 
AIx, %  38.5 ± 3.9  25.4 ± 13.1 0.001 
Aortic PWV, m/s  8.9 ± 1.7  8.1 ± 1.4 0.2 
Brachial SBP, mmHg  159.9 ± 20.6  145.9 ± 14.5 <0.05 
Brachial DBP, mmHg  91.8 ± 10.8  87.8 ± 7.3 0.2 
Heart rate, beats/min  57.4 ± 5.7  70.2 ± 10.4 <0.001 
MAP, mmHg  118.7 ± 12.8  108.1 ± 7.9 <0.01 
DBP indicates diastolic blood pressure; SBP, systolic blood pressure. Values are the mean ± SD 
or number (%). 
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Figure 7. Comparison of BP changes in patients divided according to the tertiles of 
baseline AIx. * indicates p<0.05. b DBP, brachial diastolic blood pressure; b SBP, 
brachial systolic blood pressure; c SBP, central systolic blood pressure. 
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Data for the patients in the 3rd tertile of baseline AIx 
Doxazosin Candesartan Bisoprolol ISMN 
56 
 
Figure 8. Comparison of BP changes in patients divided according to the tertiles of 
baseline PPA. * indicates p<0.05. b DBP, brachial diastolic blood pressure; b SBP, 
brachial systolic blood pressure; c SBP, central systolic blood pressure. 
Data for the patients in the 1st tertile of baseline PPA 
Data for the patients in the 3rd tertile of baseline PPA 
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6. DISCUSSION 
6.1. Asymmetric dimethylarginine as  
a marker for endothelial dysfunction and  
carotid artery intima-media thickness (Paper I) 
The main finding of Paper I was that in hypertensive patients ADMA is inde-
pendently associated with endothelial dysfunction measured by using PWA 
with pharmacological tests, carotid IMT, female gender, and total cholesterol. 
To our knowledge, this is the first study where PWA with pharmacological tests 
has been used in hypertensive patients. 
The NO is the main vasodilating, antiatherogenic, and antiproliferative 
molecule produced in the endothelium. The reduction in NO bioavailability is 
considered a hallmark of endothelial dysfunction. The production of NO by 
eNOS from L-arginine is regulated by several physiological and pathological 
pathways (Ignarro 2002). The eNOS inhibitor ADMA competes with L-arginine 
to bind the active site of eNOS, thus reducing NO availability. Clinically, 
endothelial dysfunction is evidenced by an impaired vasodilatory response to 
acetylcholine. The NO also influences wave reflection, and hence the shape of 
the waveform (Kelly et al. 1990). Administration of salbutamol causes the 
release of NO, resulting in EDV (Wilkinson et al. 2002a). It has been shown 
that administration of an eNOS inhibitor, LG-monomethyl L-arginine, mitigates 
the effect of salbutamol on wave reflection (Hayward et al. 2002) hence the 
effect of salbutamol is truly endothelium-dependent. The association between 
ADMA and EDV in our study is in accordance with the finding of a previous 
study where venous occlusion plethysmography, currently regarded as the gold 
standard for endothelial function assessment (Lind et al. 2011), was used for 
EDV assessment (Perticone et al. 2005). The independent and inverse asso-
ciation between ADMA and endothelial function assessed by using PWA with 
pharmacological tests in our study further supports this technique for assess-
ment of endothelial function.  
The aortic PWV is considered a gold standard measure of arterial stiffness 
(Laurent et al. 2006), which independently predicts outcome in hypertensive 
patients (Boutouyrie et al. 2002). However, in our study ADMA and EDV were 
not correlated with arterial stiffness. Our findings are concordant with the 
results of the PREVENCION study which confirmed that ADMA is associated 
with carotid IMT and traditional cardiovascular risk factors but not with arterial 
stiffness (Chirinos et al. 2008). To date, the correlation between EDV and aortic 
PWV has only been shown in middle-aged healthy persons (McEniery et al. 
2006) and in elderly isolated systolic hypertension patients (Wallace et al. 
2007). This could be explained by the fact that in elderly patients isolated 
systolic hypertension results from increased arterial stiffness, i.e. aortic PWV, 
which differs considerably from aortic PWV in non-isolated systolic hyper-
tension patients. The mean aortic PWV in our study subjects was 7.4 m/sec, 
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which is considerably lower than it is in isolated systolic hypertension patients 
(9.65 m/sec) (Wallace et al. 2007). Owing to the very strict inclusion criteria of 
the present study, our patients were at low or moderate total cardiovascular risk, 
which may also explain the normal range of aortic PWV. 
The present study did not reveal significant correlations between the values 
of central/brachial BP and ADMA. Several experimental studies have shown 
that the elevated plasma concentration of ADMA increases MAP (Achan et al. 
2003; Kielstein et al. 2004). This controversy can be explained by a lower 
concentration of plasma ADMA in the clinical setting because ADMA is con-
centrated intracellularly and is rapidly eliminated by DDAH. Our finding is in 
accordance with previous observational evidence that ADMA is not correlated 
with brachial BP (Chirinos et al. 2008).  
In this study we showed that ADMA is associated with an early marker for 
subclinical target organ damage, carotid IMT, in hypertension patients. It has 
been shown previously that ADMA is associated with increased carotid IMT in 
healthy subjects (Miyazaki et al. 1999). In the present study, carotid IMT was 
positively correlated with age, which is in accordance with the findings of other 
similar studies (Tanaka et al. 2001). We confirmed that EDV and carotid IMT 
are not correlated, which suggests that they measure different aspects and stages 
of early atherosclerosis (Yan et al. 2005). It is possible that endothelial dys-
function as the earliest event in the process of lesion formation precedes struc-
tural changes in the arteries; thus increase in carotid IMT could be a conse-
quence of endothelial dysfunction (Lundman et al. 2001). 
Interestingly, ADMA was increased in non-smokers compared to smokers in 
our study. Data about the relationship between ADMA and smoking status are 
conflicting (Sobczak et al. 2009). Smoking has been associated with decreased 
levels of ADMA in healthy individuals and in high risk patients (Eid et al. 
2004; Maas et al. 2007). In our study, this effect could be due to light smoking 
(less than 10 cigarettes a day). Furthermore, to minimise the acute effect of 
smoking on arterial stiffness and several biomarkers, the patients discontinued 
smoking at least 12 hours before the study. There is evidence that smoking 
enhances the expression of DDAH which may decrease ADMA levels (Maas et 
al. 2007). It has also been suggested that endothelial dysfunction caused by 
tobacco smoke is probably not related to ADMA (Sobczak et al. 2009). 
 
 
6.2. Beta-blockers, central haemodynamics and 
arterial stiffness (Paper II) 
The main findings of Paper II were that in long-term antihypertensive therapy 
both metoprolol and nebivolol reduced similarly brachial BP, however, only the 
patients receiving nebivolol showed a significant reduction in central BP. 
Nebivolol but not metoprolol succinate reduced left ventricular posterior wall 
thickness and left ventricular relative wall thickness. Change in septal wall 
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thickness correlated more significantly with change in central systolic and PP 
than with change in brachial systolic and PP. Hence, central BP reduction with 
antihypertensive treatment is more important than brachial BP reduction in 
reducing subclinical target organ damage. 
For many years, BBs have been advocated as first-line therapy for most 
patients with hypertension. This class of antihypertensive drugs flourished 
during the past 50 years as the mainstay for the prevention and treatment of 
various cardiovascular disorders such as cardiac arrhythmias, hypertension, 
myocardial infarction, and heart failure (Shah et al. 2011). Recently, the role of 
BBs in uncomplicated hypertension has been questioned. Several meta-analyses 
suggest that although BBs effectively lower brachial BP they are inferior to 
other antihypertensive drugs regarding cardiovascular outcome in uncompli-
cated hypertension (Lindholm et al. 2005; Wiysonge et al. 2007). However, the 
majority of studies (70–75%) included in these meta-analyses involved atenolol. 
The results of these meta-analyses caused the extinction of BBs as an initial 
drug of choice for hypertension management in the British Hypertension 
Society guidelines (NICE 2011). Several factors have been ascribed to the infe-
riority of atenolol (Pollare et al. 1989; Dahlöf et al. 2002). There is an accumu-
lating amount of evidence that conventional BBs, especially atenolol, despite 
having similar effects on brachial BP, are inferior to other antihypertensive 
drugs in lowering central BP (Williams et al. 2006; Mackenzie et al. 2009; 
Matsui et al. 2009; Boutouyrie et al. 2010), explaining the ‘beyond (brachial) 
BP’ paradox. However, novel vasodilating BBs (e.g. nebivolol) have been 
shown to significantly reduce central BP in short-term (4 to 5 weeks) studies 
(Dhakam et al. 2008; Mahmud and Feely 2008). Furthermore, a recent study 
showed that nebivolol is comparable to the ARB irbesartan regarding its effect 
on central BP (Vitale et al. 2012). There are no data about the effect of 
metoprolol succinate, the most widely used BB in Northern and Eastern Euro-
pean countries, on central BP. 
In the present study the effect of nebivolol and metoprolol was tested during 
a one-year period. The results of the study confirm that BBs without vaso-
dilating properties have less impact on central BP. Overall central PP reduction 
was 6 mmHg for the nebivolol group and only 0.3 mmHg for the metoprolol 
group. Moreover, the results from the CAFE study (Williams et al. 2006) indi-
cate that even a 3 mmHg reduction in central PP was associated with better car-
diovascular outcome. In the present study both treatment arms reduced similarly 
heart rate and MAP. It could be suggested that the main mechanism for the 
reduction in central BP in the nebivolol arm acted through vasodilation and 
structural remodelling of the small arteries, leading to the reduction in pulse 
wave reflection site distance and intensity. It has been demonstrated that 
nebivolol dilates the human forearm vasculature through the L-arginine path-
way (Cockcroft et al. 1995), improves resistance artery (Tzemos et al. 2001) 
and cutaneous endothelial function and small artery distensibility (Arosio et al. 
2002). At the same time, conventional BBs do not reduce PVR and sympathetic 
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activity (Burns et al. 2004), which may lead to small artery vasoconstriction and 
a higher media:lumen ratio (Schiffrin 2004).  
The AIx and PPA are related to pulse wave reflection depending on the 
amplitude and site of wave reflection and on the speed at which the pulse waves 
travel along the arterial tree. In the present study, AIx and PPA did not change 
during the one-year treatment period in either treatment arm. Previous data 
about the effect of nebivolol on AIx and PPA have been conflicting. In patients 
with isolated systolic hypertension, Dhakam et al. (2008) showed a slight 
increase of AIx and no effect on PPA after five weeks of treatment with 
nebivolol. On the contrary, Mahmud and Feely (2008) demonstrated, after 
treatment with nebivolol, a significant reduction in AIx and an increase in PPA 
in patients with essential hypertension. In the above studies, PPA and AIx were 
found to be very strongly correlated with heart rate change, which may explain 
the described controversial results. The present study also revealed a trend for 
correlation, although not significant, between heart rate change and AIx change 
for the whole study group. Moreover, the correlation was significant only for 
the nebivolol treatment arm. No correlation was detected between central PP 
change and heart rate change. This may suggest that the more pronounced 
central BP reduction in the nebivolol-treated patients appeared was a con-
comitant effect of the change in heart rate and AIx and the reduction in PVR 
rather than the effect of PWV change. It should be noted that there was already 
a difference in baseline AIx, and the reduction in heart rate was not sufficient to 
produce significant AIx change after one-year therapy, either.  
In the present study there occurred a significant reduction in aortic PWV 
after 6 months of treatment in the nebivolol group. However, after the one-year 
treatment period there was no significant difference in the change in aortic 
PWV, radial-carotid PWV (data not shown), or Tr between the two treatment 
arms. Previous studies have demonstrated a significant reduction in aortic PWV 
after treatment with nebivolol (Dhakam et al. 2008; Mahmud and Feely 2008). 
It has been suggested that the effect of BBs on aortic PWV may be related to the 
concomitant effect of reduction in MAP, sympathetic tone and heart rate. Con-
sequently, one possible explanation for the non-significant change in aortic 
PWV in the present study is also the significantly smaller reduction in heart rate 
during the one-year treatment period (approx. 6 beats/min). It should be noted 
that previous studies were of short duration, and long-term use of BBs may not 
have such a significant effect on heart rate and sympathetic activity, which are 
considered important determinants of aortic PWV. The time-dependent effect of 
BBs on vascular stiffness was also suggested in a recent review by Protogerou 
et al. (2009b). Another possibility is that in the present study baseline mean 
aortic PWV was in the normal range. Also, owing to the very strict inclusion 
criteria of the present study, the patients were at low total cardiovascular risk, 
which may also explain the weak effect of treatment on aortic PWV. 
The present study provides the first long-term evidence that the reduction in 
central systolic BP in the nebivolol group was directly related to the reduction 
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in left ventricular septal and posterior wall thickness. It has been recently 
demonstrated that compared to brachial BP central BP is a stronger determinant 
for LVH (Roman et al. 2007; Wohlfahrt et al. 2012). Data from the Strong 
Heart Study also indicate that in terms of reduction in LVH, it is more important 
to target central systolic than brachial BP (Roman et al. 2010). Moreover, the 
LIFE study demonstrated that atenolol was less effective than losartan at 
reducing LVH (Devereux et al. 2004), despite the fact that both drugs reduced 
brachial BP to a similar degree. In a small open-study, nebivolol monotherapy 
for up to 12 months resulted in a reduction in left ventricular wall thickness (Liu 
et al. 1999) and 3-month treatment with nebivolol was as effective as 
telmisartan in reducing left ventricular mass (Fountoulaki et al. 2005). 
However, a recent meta-analysis provides evidence that BBs show less regres-
sion of left ventricular mass compared to other antihypertensive drugs (Fagard 
et al. 2009). Regrettably, the results of 20 of the reviewed 31 studies were 
obtained with atenolol, the results of three studies, with metoprolol, and the 
results of only one study, with nebivolol. One plausible explanation for the 
lesser regression of LVH by BBs in the above meta-analysis is that central BP 
may not be reduced as effectively as brachial BP, which provides less afterload 
reduction with conventional BBs without vasodilating properties.  
The current study has several limitations. When the trial was designed in 
2005, there were no studies of appropriate size providing the data about the 
effect of antihypertensive drugs on central BP, derived from applanation tono-
metry, in order to undertake formal power calculation; therefore larger studies 
are needed to confirm our results. Also, 17 of the 80 study patients were with-
drawn, which is quite a high fraction. The main reason for poor treatment com-
pliance was that the study patients were relatively young with newly diagnosed 
mild-to-moderate hypertension, who did not have any symptoms or complaints 
attributable to high BP. In the case of mild adverse events after the initiation of 
treatment, they tended to withdraw their consent. Also, the inclusion criteria of 
the study were very strict and the patients were at low cardiovascular risk, 
which may explain the relatively normal mean values of central haemo-
dynamics, as well as may account for the disparity in several parameters studied 
by us and other researchers. Although both study groups were comparable with 
regard to brachial BP, there occurred a shift in central haemodynamics (AIx and 
central PP) at baseline. We cannot exclude an additional effect of the thiazide 
diuretic on the results. However, it has been proposed that diuretics have a 
neutral or minimal beneficial effect on central BP, aortic stiffness, and pulse 
wave reflection (Protogerou et al. 2009b; Matsui et al. 2009). 
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6.3. The effect of beta-blocker therapy on oxidative 
stress and inflammation (Paper III) 
The main finding of Paper III was that in long-term antihypertensive therapy 
both nebivolol and metoprolol reduced oxLDL and sICAM-1 levels in essential 
hypertension patients while only nebivolol reduced 8-isoprostane levels. 
Furthermore, the effect of metoprolol on oxLDL was associated with BP change 
while nebivolol decreased oxLDL and 8-isoprostane levels independently of BP 
reduction. To our knowledge, this is the first study to assess the long-term 
effects of nebivolol and metoprolol on OxS and inflammatory markers. 
Harmful OxS results from the imbalance between the generation of reactive 
oxygen species and the antioxidant defence systems (Zilmer et al. 2010). It has 
been shown that such OxS reduces the bioavailability of NO, leading to endo-
thelial dysfunction and atherosclerosis (Taddei et al. 1998). Thus, reversal of 
elevated OxS could represent an adjunctive target for antihypertensive treatment 
(Ono et al. 2008). Sáez et al. (2004) have previously shown that antihyper-
tensive treatment reduces OxS markers in a time-dependent manner. This 
evidence emphasises the need for long-term studies to investigate the antioxi-
dative properties of antihypertensive drugs.  
Urine isoprostanes were recently accepted by the European Food Safety 
Authority as a new biochemical marker for OxS (EFSA 2011). Isoprostanes are 
stereoisomers of prostaglandins that are formed primarily through the non-
enzymatic peroxidation of arachidonic acid by reactive oxygen species (Morrow 
2005). To our knowledge, only Napoli et al. (2008) have investigated the long-
term effect of antihypertensive drugs (ACEIs) on isoprostane levels. However, 
they measured plasma values of isoprostanes, which may overestimate true iso-
prostane levels because of the auto-oxidation of lipids (Morrow 2005). Our 
results suggest that conventional BBs have no significant effect on 8-
isoprostane levels, which is in agreement with previous short-term studies 
where metoprolol (Fahlbusch et al. 2004) and atenolol (Flammer et al. 2007; 
Pasini et al. 2007) have been used. Furthermore, in a recent study metoprolol 
increased urine isoprostane levels in patients with metabolic syndrome (Ayers et 
al. 2012). Our study showed that nebivolol decreased urinary 8-isoprostane 
levels independently of BP reduction in two respects. Firstly, reduction in 8-
isoprostane levels was not correlated with reduction in BP. Secondly, nebivolol 
reduced 8-isoprostane levels even when 8-isoprostane levels were adjusted for 
BP. Our results suggest that in long-term antihypertensive therapy nebivolol 
possesses a BP-independent effect on systemic OxS. 
Plasma levels of oxLDL are mainly influenced by degree of local OxS in 
arterial wall and by susceptibility of LDL to oxidation (Sjogren et al. 2005). 
The patients included into our study had been recently diagnosed with hyper-
tension; they were relatively young and were at low cardiovascular risk, which 
suggests low probability of the presence of plaques in the vasculature as a 
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source of oxLDL. It is plausible that increased shear stress induces oxidation of 
LDL cholesterol. Thus, reducing BP per se might reduce oxLDL. 
In hypertension several pro-inflammatory factors activate endothelial cells to 
express adhesion molecules, such as sICAM-1, which initiates recruitment of 
circulating lymphocytes to blood vessel wall. Several studies have shown that 
renin-angiotensin system inhibitors and CCBs decrease effectively sICAM-1 
levels in hypertension (Derosa et al. 2010; Martinez-Martin et al. 2011). Our 
study is the first one to assess the effect of metoprolol or nebivolol on sICAM-1 
levels in hypertensive patients. Our study suggests that both drugs potentially 
inhibit endothelial activation in vessel wall.  
There was no effect of metoprolol or nebivolol on ADMA levels in long-
term antihypertensive therapy. In addition to beta 1-adrenoceptor antagonist 
characteristics, nebivolol has beta 3-adrenoceptor agonist properties. There is 
evidence that beta 3-adrenoceptor agonist properties contribute to NO release 
while beta 1-adrenoceptor antagonism has converse effects (Evangelista et al. 
2007). These two pharmacological effects of nebivolol may account for the 
finding that in some studies nebivolol decreases ADMA levels, while in our and 
other studies ADMA concentration did not change (Oğuz et al. 2007; Kandavar 
et al. 2011; Ayers et al. 2012). Neither drug had an effect on inflammatory 
markers (CRP, white blood cell count, fibrinogen, and IL-6). It could be specu-
lated that the studied patients were indeed at a relatively low cardiovascular 
risk, according to the CRP (0.85 – 0.95 mg/L) risk categories (Pearson et al. 
2003). Furthermore, CRP values were somewhat higher in a similar study 
population (1.94 mg/L) (Cottone et al. 2007). 
There is evidence that BBs have a detrimental effect on lipoprotein and glu-
cose metabolism (Pollare et al. 1989; Bakris et al. 2004). This effect involves 
an increase in triglyceride levels and a decrease in HDL cholesterol levels. In 
our study only metoprolol increased LDL cholesterol levels. The HDL choles-
terol was decreased by both drugs. Triglyceride levels did not change signifi-
cantly in either group. It has been shown that metoprolol and atenolol have a 
similar effect on glucose, triglyceride, and HDL metabolism, which has been 
thought to account for their inferior reduction in the incidence of coronary 
artery disease in several large-scale hypertension studies (Pollare et al. 1989). 
However, there is no evidence that the change in the lipoprotein profile 
associated with BBs could negatively affect cardiovascular outcome.  
 
 
6.4. The underlying haemodynamic profile and the 
efficacy of antihypertensive treatment (Paper IV) 
We studied whether the haemodynamic profile of patients with essential hyper-
tension determines the efficacy of an alpha-blocker, a BB, an ARB, or a nitrate. 
To our knowledge, this is the first study to systematically investigate a complex 
of haemodynamic parameters (i.e. SV, CO, aortic PWV, AIx, PPA, and PVR) 
which could influence the efficacy of antihypertensive drugs. We found that 
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baseline AIx and PPA determined brachial or central BP reduction. Haemo-
dynamic profiling by baseline AIx determined BP reduction with doxazosin, 
bisoprolol, and candesartan. Haemodynamic profiling by PPA determined BP 
reduction with doxazosin, bisoprolol, and ISMN. The largest effect of haemo-
dynamic profiling by AIx and PPA which determined BP reduction was demon-
strated with bisoprolol. Baseline aortic PWV, SV, CO, and PVR did not 
determine the response to the drugs used in our study. Candesartan had the most 
impressive brachial and central BP reducing properties, regardless of the 
baseline haemodynamic profile. 
Augmentation of the pulse wave is dependent on the speed of pulse wave 
travel, the amplitude of the reflected wave, the reflectance sites, and the duration 
and pattern of ventricular ejection, including heart rate and ventricular contrac-
tility (Nichols and O’Rourke 2005). In contrast to other drugs, only bisoprolol did 
not change AIx in our study. It is well known that BBs have a negative or neutral 
effect on AIx. Due to heart rate reduction, they favour the arrival of the reflected 
wave in the relatively earlier phase in the systole, instead of the diastole (Proto-
gerou et al. 2009b; Avolio et al. 2009). As expected, only bisoprolol reduced 
heart rate significantly, which may explain our result. Nitrates can be regarded as 
the most potent drug to reduce pulse wave reflection in isolated systolic 
hypertension patients (Stokes et al. 2003). In our study, although ISMN reduced 
AIx the most, the change in AIx was smaller than expected from previous 
studies (Stokes et al. 2003). The modest effect of ISMN on AIx may explain the 
relatively small reduction in BP with this drug. Among the patients in the 3rd 
tertile of AIx, the alpha-blocker, the BB, and the ARB effectively reduced BP. 
Among these drugs, alpha-blockers and ARBs are known to cause vasodilation 
in the peripheral arteries (Lund-Johansen and Omvik 1991; Protogerou et al. 
2009b). However, the results concerning BBs are intriguing. Our results suggest 
that in patients with low AIx, BBs are comparatively less effective at reducing 
BP. In the 3rd tertile, however, BP reduction with the alpha-blocker was 
comparable to BP reduction with the ARB. These results can be explained by 
the baseline characteristics of these patients. Patients with higher AIx had 
substantially higher baseline BP. There is evidence that higher baseline BP is 
associated with a larger extent of decrease in BP (Gill et al. 1985). 
Brachial BP differs from central BP owing to the phenomenon of PPA 
(Agabiti-Rosei et al. 2007a). There is evidence that central BP predicts cardio-
vascular risk better than brachial BP does (Roman et al. 2009). Moreover, dif-
ferent antihypertensive drugs reduce central BP differentially (Agabiti-Rosei et 
al. 2007a; Mackenzie et al. 2009), which can be a better determinant of sub-
clinical organ damage and clinical outcome (Williams et al. 2006; Roman et al. 
2010). In our study, candesartan reduced both brachial and central BP the most. 
Hence, direct comparison of on-treatment central BP may underestimate the 
differential effect of study drugs on central BP because the drug classes had a 
dissimilar effect on brachial BP. Therefore, PPA could be a better measure of 
inter-drug comparison in our study because it takes into account both brachial 
65 
and central BP. All drugs except bisoprolol increased PPA, which is in accor-
dance with previous evidence (Protogerou et al. 2009b). Baseline PPA pre-
dicted the BP lowering effects of doxazosin, bisoprolol, and ISMN. However, 
the results regarding PPA as an underlying haemodynamic alteration cannot be 
considered independently. This is because it is determined by pulse wave 
reflections within the arterial tree and by arterial stiffness (Avolio et al. 2009).  
There is long-term evidence from the REASON study where atenolol and 
perindopril/indapamide reduced aortic PWV to a similar degree (Asmar et al. 
2001). The post hoc analysis of the REASON study showed that aortic PWV 
predicts BP reduction in hypertension (Protogerou et al. 2009a). However, in 
our study aortic PWV corrected for MAP was not changed by any drug and 
baseline aortic PWV did not predict the reduction of BP by the studied drugs. 
There may be several possible explanations for this controversy. The REASON 
study comprised mainly patients with diastolic and systolic hypertension while 
the patients included into our study can be classified as isolated systolic hyper-
tension patients considering their mean BP levels. It is known that arterial stiff-
ness is a major contributor to elevated BP in patients with isolated systolic 
hypertension (Franklin et al. 1997). Recent short-term data about isolated sys-
tolic hypertension patients show that antihypertensive drugs have no effect on 
aortic PWV and are less effective in reducing BP in patients with increased 
aortic PWV (Mackenzie et al. 2009). It is possible that in our study the period 
for detection of complete BP reduction and “destiffening” (6 weeks) was inade-
quate (McEniery et al. 2009).  
In our study, CO did not predict BP reduction with antihypertensive treat-
ment, which would have been expected with bisoprolol. The failure to show CO 
as a predictor of BP reduction with the BB in our study may be due to the neu-
tral effect of bisoprolol on CO. The mean baseline CO in our study patients was 
6.0 L/min, which is smaller than it was in a similar group of patients (6.4 
L/min) (Kim et al. 2011) and even in young normotensive subjects (6.9 L/min) 
(McEniery et al. 2005b). It is possible that the compensatory mechanism, i.e. 
increase in stroke volume (Δ for bisoprolol: + 14.4 mL) mitigated the decrease  
of CO with bisoprolol. Furthermore, it is possible that in young patients  
with isolated systolic hypertension, in whom CO is significantly higher 
(8.1 ± 1.9 L/min) (McEniery et al. 2005b), bisoprolol could be more effective in 
reducing CO; hence CO could determine BP reduction in these patients. The 
PVR is positively related to MAP and inversely related to CO. While doxazosin 
reduced MAP similarly to the other drugs it significantly increased CO, which 
might have contributed to its larger effect on PVR in our study. However, 
haemodynamic profiling with the use of PVR failed to predict BP reduction 
with doxazosin.  
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7. CONCLUSIONS 
1. Asymmetric dimethylarginine was independently associated with endothelial 
function measured by using pulse wave analysis with pharmacological tests 
and carotid artery intima-media thickness. Our results suggest that asym-
metric dimethylarginine is a marker for endothelial dysfunction and intima-
media thickening in hypertensive patients. 
2. In long-term (one-year) antihypertensive therapy metoprolol succinate and 
nebivolol had similar effects on brachial blood pressure and arterial stiffness. 
Only nebivolol reduced significantly central systolic, diastolic, and pulse 
pressure. In addition, long-term antihypertensive therapy with nebivolol, but 
not metoprolol succinate, reduced left ventricular posterior wall thickness 
and left ventricular relative wall thickness. Our results demonstrate that the 
vasodilating beta-blocker nebivolol is superior to the conventional beta-
blocker metoprolol succinate regarding their effects on central blood pres-
sure and reduction of target organ damage. 
3. Change in interventricular septal wall thickness correlated more significantly 
with change in central systolic and pulse pressure than with change in bra-
chial systolic and pulse pressure. Our results indicate that central blood pres-
sure reduction with antihypertensive treatment is more important than 
brachial blood pressure reduction in reducing target organ damage. 
4. In long-term (one-year) antihypertensive treatment both nebivolol and 
metoprolol succinate reduced the levels of oxidized low-density lipoprotein 
and soluble intercellular adhesion molecule-1. However, only nebivolol 
reduced urinary 8-isoprostane levels. Nebivolol reduced oxidized low-
density lipoprotein and 8-isoprostanes independently of blood pressure 
reduction, while metoprolol succinate had blood pressure-dependent effects 
on oxidized low-density lipoprotein. This finding demonstrates that in the 
long-term treatment of essential hypertension nebivolol is superior to 
metoprolol succinate regarding their systemic antioxidant influences. 
5. Augmentation index and pulse pressure amplification as underlying haemo-
dynamic alterations determined the reduction of brachial systolic, diastolic, 
and central systolic blood pressure with antihypertensive treatment. Baseline 
augmentation index predicted blood pressure reduction for doxazosin and 
candesartan, and particularly for bisoprolol. Baseline pulse pressure ampli-
fication predicted the reduction in blood pressure for doxazosin, bisoprolol, 
and isosorbide mononitrate. These results suggest that haemodynamic pro-
filing with the use of augmentation index may be especially beneficial in 
case beta-blockers are considered for treatment of essential hypertension. 
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9. SUMMARY IN ESTONIAN 
Tsentraalse hemodünaamika, arterite jäikuse ja oksüdatiivse 
stressi raviaspektid hüpertensiooniga patsientidel 
Kõrgenenud arteriaalne vererõhk on oluliseks kardiovaskulaarseks riskiteguriks. 
Arteriaalne hüpertensioon on püsiv vererõhu tõus ≥140/90 mmHg. Lisaks kõr-
genenud vererõhuväärtustele on hüpertensiooniga haigetel oluline hinnata ka 
teisi kardiovaskulaarseid riskitegureid ning subkliinilist organkahjustust (näit. 
unearteri sise- ja keskkesta ning vasaku vatsakese seina paksenemist), mis 
summaarselt tõstavad individuaalse patsiendi kardiovaskulaarset riski ja määra-
vad edasise ravistrateegia. Samas ei selgita mitmed traditsioonilised riskitegurid 
(suitsetamine, hüperkolesteroleemia jne.) täielikult patsiendi kardiovaskulaarset 
riski. 
Veresoonte sisemine kiht, endoteel, toodab lämmastikoksiidi, mis on orga-
nismi võimsaimaks veresooni lõõgastavaks ja antiaterogeenseks molekuliks. 
Mitmete riskitegurite, hüpertensiooni ja südame-veresoonkonna haiguste puhul 
on endoteeli funktsioon häirunud. Endoteeli funktsiooni häirumine on vere-
sooneseina kahjustuse varaseim etapp, mis põhjustab ka arterite jäikuse suure-
nemist ja subkliinilise organkahjustuse teket, mis on oluliselt seotud hüper-
tensioonihaigete kardiovaskulaarse suremusega. Seega on varajane endoteeli 
funktsiooni hindamine kliiniliselt olulise tähtsusega. Uudseks endoteeli funkt-
siooni peegeldavaks biomarkeriks on asümmeetriline dimetüülarginiin, mis on 
lämmastikoksiidi sünteesi inhibiitor. Lisaks on hüpertensiooni puhul suure-
nenud oksüdatiivse stressi (sh. oksüdeeritud LDL-kolesterooli ja 8-isopros-
taanide) ning subkliinilise põletiku (sh. C-reaktiivse valgu ja rakuvahelise 
adhesiooni molekul-1) tase, mis põhjustavad veresoonte kahjustust ning on ise-
seisvalt seotud kardiovaskulaarsete tüsistustega. Seega oksüdatiivse stressi ja 
subkliinilise põletiku vähendamine omavad hüpertensiooniga patsientidel sood-
sat toimet. 
Mitmed meta-analüüsid on näidanud, et vererõhu langetamine iseenesest 
vähendab hüpertensiooniga patsiendi kardiovaskulaarset riski. Samas vaatamata 
heale ravisoostumusele saavutatakse vähem kui 30% ravitavatest hüperten-
siooniga patsientidest eesmärkvererõhk (<140/90 mmHg). Hüpertensiooniga 
patsiente iseloomustab normist kõrvalekalduv hüpertensiooni hemodünaamiline 
profiil. Mitmed uuringud on näidatud, et patsiendi hüpertensiooni hemo-
dünaamiline profiil määrab vererõhu languse antihüpertensiivse raviga. Seega 
võib patsientide hüpertensiooni hemodünaamilise profiili määramine viia efek-
tiivsema vererõhu normaliseerumiseni ja vajaolevate antihüpertensiivsete ravi-
mite vähenemiseni. 
Tavaliselt mõõdetakse vererõhku õlavarrelt. Samas vererõhk õlavarrearteris 
(perifeerne arter) erineb oluliselt vererõhust aordis (tsentraalne arter) arterite 
jäikuse ja pulsilaine peegeldumise tõttu. Tsentraalne vererõhk on perifeersest 
vererõhust olulisem subkliinilise organkahjustuse tekkes ja kardiovaskulaarse 
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riski määramisel. On näidatud, et antihüpertensiivsed ravimid eristuvad ka oma 
toime poolest tsentraalsele vererõhule. Peamised antihüpertensiivsed ravimi-
klassid langetavad efektiivselt tsentraalset vererõhku. Samas beeta-blokaatorite 
kohta on vastukäiväid andmeid. Klassikalised beeta-blokaatorid (näiteks ate-
nolool) omavad neutraalset või minimaalset toimet tsentraalsele vererõhule. 
Atenolooli nõrka toimet tsentraalsele vererõhule seostatakse uuringutega, kus 
atenolool on tüsistumata essentsiaalse hüpertensiooniga patsientidel vähen-
danud kardiovaskulaarseid tüsistusi vähem võrreldes teiste antihüpertensiivsete 
ravimitega. Siiski on lühiaegsetes uuringutes näidatud, et uuemad vasodila-
teerivad beeta-blokaatorid (näiteks nebivolool) langetavad efektiivselt tsent-
raalset vererõhku. Puuduvad andmed metoprolool suktsinaadi kohta, mis on 
Ida- ja Põhja-Euroopas enim kasutatav klassikaline beeta-blokaator. 
 
Uurimistöö eesmärgid 
1. Uurida asümmeetrilise dimetüülarginiini, unearteri sise- ja keskkesta paksuse 
ning endoteeli funktsiooni vahelisi seoseid hüpertensiooniga patsientidel. 
2. Hinnata nebivolooli ja metoprolooli pikaaegset toimet tsentraalsele vere-
rõhule, arterite jäikusele ja südame vasaku vatsakese seina paksusele. 
3. Hinnata seost tsentraalse vererõhu languse ning südame vasaku vatsakese 
seina paksuse vähenemise vahel pikaaegse antihüpertensiivse ravi käigus. 
4. Võrrelda nebivolooli ja metoprolooli toimet oksüdatiivsele stressile ja 
põletikule pikaaegsel kasutusel hüpertensiooniga patsientidel. 
5. Testida, kas hüpertensiooniga patsiendi algne hüpertensiooni hemodünaami-
line profiil määrab alfa-blokaatori (doksasosiin), beeta-blokaatori (biso-
prolool), angiotensiin II retseptori blokaatori (kandesartaan) ning nitraadi 
(isosorbiid mononitraat) antihüpertensiivset efektiivsust. 
 
Patsiendid ja meetodid 
Uuringus osales 133 hüpertensiooniga patsienti, keda uuriti 2 etapis. Esimeses 
etapis viidi läbi paralleelgruppidega topeltpime randomiseeritud aktiivselt kont-
rollitud ühe keskuse IV faasi uuring. Uuringusse kaasati 80 mees- ning nais-
soost ravimata kerge kuni mõõduka astmega hüpertensiooniga patsienti vanuses 
30–65 aastat. Uuringu peamisteks väljaarvamiskriteerimiteks olid sekundaarne 
hüpertensioon, diabeet, ülekaal, südame isheemiatõbi, südamepuudulikkus, 
astma, hüperkolesteroleemia ning teised olulised kaasuvad haigused. Uuritavad 
randomiseeriti saama nebivolooli 5 mg üks kord päevas või metoproloolsuktsi-
naati 50 mg üks kord päevas 1 aasta jooksul. Juhul kui õlavarre vererõhu tase 
püsis uuringu käigus >140/90 mmHg, sai ravimidoosi suurendada (metoprolooli 
grupis ad 100 mg üks kord päevas) ning lisada hüdrokloortiasiidi 12.5–25 mg 
üks kord päevas (mõlemas grupis). Õlavarre vererõhu, pulsilaine kiiruse, 
pulsilaine analüüsi ning ehhokardiograafia mõõtmised toimusid vahetult enne 
randomiseerimist ning poole ja ühe aasta möödudes randomiseerimisest. Oksü-
datiivse stressi ja põletiku markerite ning unearterite sise- ja keskkesta paksuse 
mõõtmised toimusid randomiseerimisel ja pärast 1-aastast ravimikasutust. 
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Randomiseerimiseelselt teostati uuritavatel lisaks endoteeli funktsiooni mõõt-
mised. Teises etapis viidi läbi ristuva disainiga topeltpime randomiseeritud 
platseebo-kontrollitud kahe keskuse IV faasi uuring. Uuriti 53 ravimata hüper-
tensiooniga patsienti vanuses 18–80 aastat. Uuringu väljalülitamiskriteerimiteks 
olid õlavarre vererõhk >200/110 mmHg, sekundaarne hüpertensioon, diabeet, 
astma, südamepuudulikkus ning teised olulised kaasuvad haigused. Patsiendid 
randomiseeriti saama doksasosiini 4 mg, bisoprolooli 5 mg, kandesartaani 
16 mg, isosorbiidmononitraati 50 mg ja platseebot üks kord päevas. Iga ravimit 
ja platseebot tarvitati 6 nädalat, kuni kõik ravimifaasid olid läbitud (kokku 30 
nädalat). Uuringu alguses ja pärast iga ravimifaasi teostati uuritavatele õlavarre 
vererõhu, pulsilaine analüüsi, pulsilaine kiiruse ning mitteinvasiivsed südame 
minutimahu, löögimahu ning perifeerse vaskulaarse resistentsuse mõõtmised.  
Kõik uuringud viidi läbi kella 8–11 vahelisel ajal, pärast üleööpaastu. Õla-
varre vererõhk mõõdeti pärast 15-minutilist rahuolekut. Pulsilaine analüüs teos-
tati Sphygmocor Px (Atcor Medical, Austraalia) aparatuuriga. Aplanatsiooni 
tonomeetriga registreeriti pulsilaine radiaalarterilt ning, kasutades valideeritud 
ülekandefunktsiooni, tuletati tsentraalse pulsilaine parameetrid (mh. augmentat-
siooni indeks, mis iseloomustab pulsilainete tagasipeegeldumist) ning tsent-
raalse vererõhu väärtused. Pulsirõhu amplifikatsioon, mis iseloomustab arterite 
jäikust ja pulsilainete tagasipeegeldumist, arvutati õlavarre pulsirõhu jagamisel 
tsentraalse pulsirõhuga. Endoteeli funktsiooni uurimiseks hinnati 400 μg sal-
butamooli inhalatsiooni (stimuleerib lämmastikoksiidi vabanemist endoteelist) 
toimet augmentatsiooni indeksile. Sama aparatuuri kasutati ka pulsilaine leviku 
kiiruse hindamiseks aordis. Selle mõõtmiseks registreeriti aplanatsioonitono-
meetriga pulsilained ühisunearterilt ja -reiearterilt samaaegse elektrokardio-
grammi registreerimisega. Pulsilaine tekke ajastuse ja pulsilaine poolt läbitud 
vahemaa andmete põhjal arvutatati pulsilaine leviku kiirust aordis. Valideeritud 
Innocor aparatuuri (Innovision A/S, Taani) kasutati mitteinvasiivseks südame 
minutimahu, löögimahu ning perifeerse vaskulaarse resistentsuse hindamiseks. 
Ehhokardiograafilised mõõtmised viidi läbi 2 spetsialisti poolt kasutades  
3.5-MHz andurit ning ultraheli aparatuuri (Sonos 7500, Philips Medical 
Systems, Inc., USA). Unearteri sise- ja keskkesta paksuse mõõtmiseks salvestati 
12-MHz anduriga sama ultraheli aparaatuuri kasutades mõlemas ühisunearteris 
eesmised, külgmised ja tagakülgmised projektsioonid. Seejärel toimus hilisem 
digitaalse videosalvestuse analüüs Ida-Soome Ülikoolis (Kuopio, Soome) 
Prosound tarkvaraga (Caltech, USA). 
 
Uurimistöö tulemused ja järeldused 
1. Asümmetriline dimetüülarginiin oli sõltumatult seotud endoteeli funktsioo-
niga ning unearteri sise- ja keskkesta paksusega. Antud tulemused näitavad, 
et asümmeetriline dimetüülarginiin on endoteeli funktsiooni ja unearteri sise- 
ja keskkesta paksuse marker hüpertensiooniga patsientidel. 
2.  Metoprolool ja nebivolool langetasid võrdselt õlavarrelt mõõdetud vererõhku 
ja arterite jäikust pikaaegse antihüpertensiivse ravi käigus. Vaid nebivolool 
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langetas tsentraalset süstoolset, diastoolset ja pulsirõhku. Nebivolool, aga 
mitte metoprolool vähendas vasaku vatsakese tagumise seina paksust ja 
vasaku vatsakese suhtelist seina paksust. Seetõttu on tüsistumata arteriaalse 
hüpertensiooni ravis otstarbekas eelistada vasodilateerivaid, mitte klassikalisi 
beeta-blokaatoreid.  
3. Vatsakestevahelise seina paksuse vähenemine oli oluliselt tugevamini seotud 
tsentraalse süstoolse ja pulsirõhu vähenemisega võrreldes õlavarrelt mõõde-
tud vererõhu vähenemisega pikaajalisel antihüpertensiivsel ravil. Antud 
tulemus kinnitab, et tsentraalse vererõhu langetamine antihüpertensiivse 
raviga on olulisem subkliinilise organkahjustuse vähendamisel võrreldes õla-
varrelt mõõdetud vererõhuga. 
4. Pikaajalisel nebivolooli ja metoprolooli kasutamisel langetasid mõlemad 
ravimid plasma oksüdeeritud LDL-kolesterooli ning rakuvahelise adhesiooni 
molekul-1 taset. Samas vaid nebivolool langetas 8-isoprostaanide taset 
uriinis. Metoprolool langetas oksüdeeritud LDL-kolesterooli sõltuvalt vere-
rõhu langusest. Nebivolooli toime oksüdeeritud LDL-kolesterooli ja 8-iso-
prostaanide tasemele oli vererõhu langusest sõltumatu. Seega vähendavad 
vasodilateerivad beeta-blokaatorid lokaalset ja süsteemset oksüdatiivset 
stressi sõltumatult vererõhu langusest. 
5. Hüpertensiooniga patsiendi arterialse süsteemi hemodünaamilistest para-
meetritest määrasid augmentatsiooni indeks ja pulsirõhu amplifikatsioon 
õlavarrelt mõõdetud ning tsentraalse vererõhu langust antihüpertensiivse 
raviga. Augmentatsiooni indeks ennustas vererõhu langust doksasosiini, 
kandesartaani ja eriti bisoprolooli puhul. Pulsirõhu amplifikatsioon ennustas 
vererõhu langust doksasosiini, bisoprolooli ja isosorbiid mononitraadi puhul. 
Seega võib hüpertensiooni hemodünaamilise profiili hindamisest olla enim 
kasu beeta-blokaatori määramisel hüpertensiooniga patsiendile. 
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